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A B S T R A C T
Background
Cytomegalovirus (CMV) is a significant cause of morbidity and mortality in solid organ transplant recipients. Pre-emptive treatment of
patients with CMV viraemia using antiviral agents has been suggested as an alternative to routine prophylaxis to prevent CMV disease. This
is an update of a Cochrane review first published in 2005.
Objectives
This review was conducted to evaluate the eBicacy of pre-emptive treatment with antiviral medications in preventing symptomatic CMV
disease.
Search methods
For this update, we searched the Cochrane Renal Group's Specialised Register (to 16 January 2013) through contact with the Trials' Search
Co-ordinator using search terms relevant to this review.
Selection criteria
We included randomised controlled trials (RCTs) of pre-emptive treatment compared with placebo, no specific treatment or with antiviral
prophylaxis in solid organ transplant recipients.
Data collection and analysis
Four authors assessed the quality and extracted all data. Analyses used a random-eBects model and results were expressed as risk ratio
(RR) and 95% confidence intervals (CI).
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Main results
We identified 15 eligible studies (1098 participants). Of these, six investigated pre-emptive treatment versus placebo or treatment of CMV
when disease occurred (standard care), eight looked at pre-emptive treatment versus antiviral prophylaxis, and one reported on oral versus
intravenous pre-emptive treatment.
Assessment of risk of bias identified that the processes reported for sequence generation and allocation concealment were at low risk
of bias in only five and three studies, respectively. All studies were considered to be at low risk of attrition bias, and seven studies were
considered to be at low risk of bias for selective reporting. Only one study reported adequate blinding of participants and personnel; no
study reported blinding of outcome assessment.
Compared with placebo or standard care, pre-emptive treatment significantly reduced the risk of CMV disease (6 studies, 288 participants:
RR 0.29, 95% CI 0.11 to 0.80) but not acute rejection (3 studies, 185 participants: RR 1.21, 95% CI 0.69 to 2.12) or all-cause mortality (3 studies,
176 participants: RR 1.23, 95% CI 0.35 to 4.30). Comparative studies of pre-emptive therapy versus prophylaxis showed no significant
diBerences in preventing CMV disease between pre-emptive and prophylactic therapy (7 studies, 753 participants: RR 1.00, 95% CI 0.36 to
2.74) but there was significant heterogeneity (I2 = 63%). Leucopenia was significantly less common with pre-emptive therapy compared
with prophylaxis (6 studies, 729 participants: RR 0.42, 95% CI 0.20 to 0.90). Other adverse eBects did not diBer significantly or were not
reported. There were no significant diBerences in the risks of all-cause mortality, gra@ loss, acute rejection and infections other than CMV.
Authors' conclusions
Few RCTs have evaluated the eBects of pre-emptive therapy to prevent CMV disease. Pre-emptive therapy is eBective compared with
placebo or standard care. Despite the inclusion of five additional studies in this update, the eBicacy of pre-emptive therapy compared with
prophylaxis to prevent CMV disease remains unclear due to significant heterogeneity between studies. Additional head-to-head studies
are required to determine the relative benefits and harms of pre-emptive therapy and prophylaxis to prevent CMV disease in solid organ
transplant recipients.
P L A I N   L A N G U A G E   S U M M A R Y
Pre-emptive treatment with antiviral agents can help to reduce the risk of cytomegalovirus disease
Cytomegalovirus (CMV) is the most common cause of viral disease in people who have received kidney, heart, liver, lung or pancreas
transplants (solid organ transplants). CMV is a major cause of illness and death during the first six months a@er transplantation.
Characteristics of CMV include fever, very low white blood cell counts (leucopenia) and very low numbers of platelets (thrombocytopenia)
with or without specific organ involvement.
Two main strategies to prevent CMV disease have been adopted: giving daily low doses of an antiviral agent (prophylaxis) to all organ
transplant recipients, or prescribing an antiviral agent when an organ transplant recipient develops laboratory-confirmed evidence of
infection during routine screening (pre-emptive treatment).
This review looked at the benefits and harms of pre-emptive treatment with antiviral agents in preventing CMV disease in solid organ
transplant recipients. We identified six studies (288 participants) that compared pre-emptive treatment with placebo or usual care. Pre-
emptive treatment significantly reduced the risk of CMV disease. There were also eight studies (784 participants) that compared pre-
emptive treatment with antiviral prophylaxis. There were no significant diBerences in the risks of CMV disease or death between pre-
emptive therapy and prophylaxis. However, variation in results among studies meant that there is some uncertainty about these results.
Low white blood cell counts were much less common with pre-emptive treatment.
More studies comparing pre-emptive treatment with antiviral prophylaxis are still required to provide greater certainty about the relative
eBectiveness of pre-emptive therapy compared with prophylaxis.
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Summary of findings for the main comparison.   Pre-emptive medication for cytomegalovirus (CMV) viraemia compared to placebo/no treatment to
prevent CMV disease in solid organ transplant recipients
Pre-emptive medication for CMV viraemia versus placebo/no treatment to prevent CMV disease in solid organ transplant recipients
Patient or population: solid organ transplant recipients with CMV viraemia 
Settings: tertiary hospitals 
Intervention: pre-emptive medication for CMV viraemia to prevent CMV disease 
Comparison: placebo/no treatment
Illustrative comparative risks* (95% CI)
Assumed risk Corresponding risk
Outcomes
Placebo/no treatment Pre-emptive medication for CMV vi-
raemia
Risk ratio 
(95% CI)
No of partici-
pants 
(studies)
Quality of the
evidence 
(GRADE)
Comments
Study population
295 per 1000 85 per 1000 
(32 to 236)
Moderate
All sympto-
matic CMV
disease
359 per 1000 104 per 1000 
(39 to 287)
0.29 
(0.11 to 0.8)
288 (6) ⊕⊕⊝⊝ 
low1,2
 
Study population
107 per 1000 44 per 1000 
(6 to 282)
Moderate
CMV organ
involvement
48 per 1000 20 per 1000 
(3 to 126)
0.41 
(0.06 to 2.63)
217 (5) ⊕⊕⊝⊝ 
low1,2
 
Study populationAcute rejec-
tion
172 per 1000 208 per 1000 
(119 to 365)
1.21 
(0.69 to 2.12)
185 (3) ⊕⊕⊝⊝ 
low1,2
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Moderate
191 per 1000 231 per 1000 
(132 to 405)
Study population
45 per 1000 55 per 1000 
(16 to 193)
Moderate
All-cause
mortality
26 per 1000 32 per 1000 
(9 to 112)
1.23 
(0.35 to 4.3)
176 (3) ⊕⊕⊝⊝ 
low1,2
 
Study population
95 per 1000 27 per 1000 
(1 to 510)
Moderate
GraC loss
95 per 1000 27 per 1000 
(1 to 508)
0.28 
(0.01 to 5.35)
36 (1) ⊕⊝⊝⊝ 
very low1,2
 
Study population
17 per 1000 26 per 1000 
(3 to 260)
Moderate
Leucopenia
24 per 1000 37 per 1000 
(4 to 369)
1.54 
(0.16 to 15.36)
114 (2) ⊕⊕⊝⊝ 
low1,2
 
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the as-
sumed risk in the comparison group and the relative risk of the intervention (and its 95% CI). 
CI: confidence interval; RR: risk ratio
GRADE Working Group grades of evidence 
High quality: Further research is very unlikely to change our confidence in the estimate of effect. 
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. 
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. 
Very low quality: We are very uncertain about the estimate
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1No studies used blinding of participants, investigators and outcome assessors and most reported unclear allocation concealment
2Small patient numbers
 
 
Summary of findings 2.   Pre-emptive medication compared to prophylaxis for cytomegalovirus (CMV) viraemia to prevent CMV disease in solid organ
transplant recipients
Pre-emptive medication versus prophylaxis for CMV viraemia to prevent CMV disease in solid organ transplant recipients
Patient or population: solid organ transplant recipients with CMV viraemia 
Settings: tertiary hospitals 
Intervention: pre-emptive medication for CMV viraemia to prevent CMV disease 
Comparison: prophylaxis
Illustrative comparative risks* (95% CI)
Assumed risk Corresponding risk
Outcomes
Prophylaxis Pre-emptive medication
Risk ratio 
(95% CI)
No of partici-
pants 
(studies)
Quality of the
evidence 
(GRADE)
Comments
Study population
106 per 1000 108 per 1000 
(45 to 258)
Moderate
All symptomatic
CMV disease
88 per 1000 90 per 1000 
(38 to 215)
1.02 
(0.43 to 2.44)
753 (7) ⊕⊕⊝⊝ 
low1,2
 
Study population
33 per 1000 39 per 1000 
(18 to 82)
Moderate
All-cause mor-
tality
29 per 1000 35 per 1000 
(16 to 73)
1.19 
(0.56 to 2.51)
753 (7) ⊕⊕⊝⊝ 
low1,3
 
Study populationGraC loss
51 per 1000 55 per 1000 
(21 to 145)
1.07 
(0.41 to 2.82)
753 (7) ⊕⊕⊝⊝ 
low1,3
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Moderate
55 per 1000 59 per 1000 
(23 to 155)
Study population
165 per 1000 203 per 1000 
(124 to 334)
Moderate
Acute rejection
166 per 1000 204 per 1000 
(125 to 337)
1.23 
(0.75 to 2.03)
693 (6) ⊕⊕⊝⊝ 
low1,3
 
Study population
238 per 1000 100 per 1000 
(48 to 214)
Moderate
Leucopenia
207 per 1000 87 per 1000 
(41 to 186)
0.42 
(0.2 to 0.9)
729 (6) ⊕⊕⊕⊝ 
moderate1
 
Study population
150 per 1000 149 per 1000 
(18 to 1000)
Moderate
D+/R- serosta-
tus: sympto-
matic CMV
94 per 1000 93 per 1000 
(11 to 754)
0.99 
(0.12 to 8.02)
39 (2) ⊕⊝⊝⊝ 
very low1,3
 
Study population
87 per 1000 18 per 1000 
(2 to 153)
Moderate
D+ or D-/R+
serostatus:
symptomatic
CMV
85 per 1000 18 per 1000 
0.21 
(0.02 to 1.76)
93 (2) ⊕⊝⊝⊝ 
very low1,3
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(2 to 150)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the as-
sumed risk in the comparison group and the relative risk of the intervention (and its 95% CI). 
CI: confidence interval; RR: risk ratio
GRADE Working Group grades of evidence 
High quality: Further research is very unlikely to change our confidence in the estimate of effect. 
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. 
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. 
Very low quality: We are very uncertain about the estimate
1No studies reported blinding of participants, investigators or outcome assessors and most did not report adequate allocation concealment
2Significant heterogeneity between studies
3Small numbers of events
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B A C K G R O U N D
Description of the condition
Cytomegalovirus (CMV) infection is an important cause of morbidity
and mortality in solid organ transplant recipients, with up to 75% of
patients developing or reactivating infection a@er transplantation
(Fishman 2007). The risk of developing CMV is well established. CMV
infection and disease are seen most commonly in CMV negative
recipients of CMV seropositive organs and in recipients treated
with anti-lymphocyte therapy (EBPG 2000). Recipients who have
a positive serostatus for CMV, regardless of donor status, are
at intermediate risk of developing or re-developing CMV; donor
negative organs and negative serostatus recipients are at the lowest
risk of infection (Fishman 2007).
CMV can lead to direct or indirect eBects of infection. Direct eBects
include CMV syndrome (encompassing fever, myelosuppression,
myalgia and arthralgia), tissue invasive CMV disease leading to
hepatitis, gastroenteritis, pneumonitis and potentially any other
organ or body tissue, and finally, mortality (Eid 2010). CMV infection
may also be associated with indirect eBects including acute and
chronic organ rejection, gra@ loss, opportunistic infections other
than CMV, and new onset diabetes mellitus (Eid 2010; Kotton 2010).
Description of the intervention
Pre-emptive therapy involves the detection of active CMV
replication through routine surveillance using an appropriately
sensitive and specific test (such as real-time polymerase chain
reaction (PCR) or pp65 antigenaemia assay) with established
thresholds for CMV infection. Once the CMV infection threshold has
been reached, treatment with antiviral medications (valganciclovir
or ganciclovir) is initiated with the aim of preventing progression to
symptomatic CMV disease (Humar 2009).
How the intervention might work
The intervention aims to direct treatment to patients who are
most at risk of developing CMV disease, rather than administering
universal prophylaxis that would include some patients who would
never develop CMV disease. By targeting higher risk patients it
should be possible to direct therapy to those in need, to reduce the
risk of adverse eBects associated with long-term antiviral therapy,
and possibly, to lower the cost of therapy. Pre-emptive therapy may
also reduce the numbers of patients who develop late onset CMV
disease a@er prophylaxis is ceased (Eid 2010).
Why it is important to do this review
Pre-emptive treatment of recipients with CMV viraemia detected
on surveillance has been advocated as an alternative to antiviral
prophylaxis because only recipients who develop CMV infection,
and are thus at high risk of CMV disease, are treated. This approach
exposes patients to a lower risk of adverse eBects of medications
and may reduce the risk of the emergence of resistant strains of
CMV and of late onset CMV disease, which has been reported as
increasing in frequency in solid organ transplant recipients (Arthurs
2007; Arthurs 2008; Eid 2010; Kotton 2010). Late onset CMV disease
is seen in about 10% of patients given 12 weeks of oral ganciclovir
prophylaxis but is rare following pre-emptive regimens.
It has been argued that pre-emptive treatment in CMV negative
recipients of CMV positive organs allows controlled viral replication
to occur before antiviral medications are administered (Limaye
2000). This could result in the development of specific immune
responses which are important in the prevention of future episodes
of CMV disease.
Pre-emptive therapy appears particularly attractive in recipients at
low risk of CMV disease such as CMV positive recipients of kidney
transplants who are not receiving antibody immunosuppression
because their risk of CMV disease is only about 7% (Waiser 1998).
However, pre-emptive therapy relies on the timely availability of
sensitive and reliable methods for detecting CMV viraemia so that
treatment based on identifying CMV infection can be initiated
before CMV disease develops. Furthermore, the cost of screening
may be higher than prophylaxis even though the cost of antiviral
medication is lower (Eid 2010). Pre-emptive therapy potentially
exposes patients to periods of CMV infection and possibly indirect
eBects of CMV infection. Moreover, treatment method relies on the
patient's compliance with regular screening and easy access to a
transplant centre if treatment is required.
Prophylaxis is currently the predominant intervention used to
prevent CMV disease. Routine antiviral prophylaxis is associated
with an increased risk of adverse eBects of medications, the
development of CMV resistance and late onset CMV disease when
prophylaxis is discontinued and is costly (Arthurs 2008; Emery 2001;
Hart 2001). Prophylaxis for all organ transplant recipients (except
CMV negative recipients of CMV negative donors) means that a
proportion of patients will receive potentially harmful medications
when they were not destined to develop CMV disease.
In view of the actual and potential advantages and disadvantages
of pre-emptive therapy and of prophylaxis to prevent CMV disease,
a systematic review was warranted to ascertain the eBicacy of
pre-emptive therapy and the relative benefits and harms of these
therapies for preventing CMV disease in solid organ transplant
recipients.
This Cochrane systematic review should be considered in
conjunction with the Cochrane review Antiviral therapy for
preventing CMV disease in solid organ transplants recipients
(Hodson 2013) which looked at the benefits and harms of
prophylaxis with antiviral medications to prevent CMV disease.
Hodson 2013 includes 37 studies (4342 participants). Prophylaxis
with ganciclovir, valaciclovir or aciclovir (19 studies, 1981
participants) significantly reduced the risk of CMV disease, CMV
infection and all-cause mortality compared with placebo or
no specific therapy. In direct comparison studies, ganciclovir
was significantly more eBective than aciclovir (7 studies, 1113
participants). Valganciclovir was as eBective as ganciclovir (1 study,
364 participants) and extended duration valganciclovir significantly
reduced the risk of CMV disease compared with three months (2
studies, 454 participants).
O B J E C T I V E S
The aim of this review was to evaluate the benefits and harms of
pre-emptive treatment of CMV viraemia to prevent CMV disease,
all-cause mortality and the indirect eBects of CMV infection
(acute rejection, gra@ loss, opportunistic infections) in solid organ
transplant recipients and to assess the comparative eBects of pre-
emptive treatment regimens and routine CMV prophylaxis with
antiviral medications.
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M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) and quasi-RCTs
(trials in which allocation was obtained by alternation, alternate
medical records, date of birth or other predictable methods) only.
Types of participants
Studies enrolling any type of solid organ transplant recipient, adult
or paediatric, were included.
Types of interventions
We included RCTs of pre-emptive treatment compared with
placebo or standard care, pre-emptive treatment compared
with antiviral prophylaxis, and diBerent pre-emptive treatment
regimens (diBerent antiviral agents used for pre-emptive
treatment, diBerent doses, diBerent routes of administration) in
solid organ transplant recipients.
Types of outcome measures
The eBects of these interventions were tested on the following
outcomes:
• all-cause mortality• death due to CMV disease• CMV disease• time to development of CMV disease• gra@ loss• acute rejection• other infections• adverse eBects of medications.
For the purpose of analysis, pre-emptive treatment was defined as
routine testing for CMV viraemia using any test and commencing
antiviral treatment if viraemia was detected. Prophylaxis was
defined as the regular administration of an appropriate antiviral
medication for a period of time immediately post transplantation.
Other definitions for the meta-analysis were comparable with those
reported previously by Ljungman 2002. CMV infection was defined
as isolation of CMV in any tissue or body fluid by an appropriately
sensitive and specific test. CMV DNAemia was defined as detection
of CMV DNA in whole blood, plasma, peripheral blood leukocytes
or buBy coat specimens by an appropriately sensitive and specific
technique such as real time polymerase chain reaction (RT-PCR).
CMV disease was defined as CMV infection together with CMV
syndrome (fever and bone marrow suppression) and/or tissue
invasive CMV confirmed on histopathology.
Search methods for identification of studies
Original review (2005)
We searched the following resources without language restriction.
• The Cochrane Renal Group's Specialised Register• The Cochrane Central Register of Controlled Trials (CENTRAL in
The Cochrane Database of Systematic Reviews issue 2, 2005).• MEDLINE (1966 to February 2005).
• EMBASE (1980 to February 2005).
The Trials Search Co-ordinator ensured that all relevant studies
had been identified. Additional studies were located through article
reference lists and from abstracts from international meetings.
Review update (2013)
For this update, we searched the Cochrane Renal Group's
Specialised Register (to 16 January 2013) through contact with
the Trials' Search Co-ordinator using search terms relevant to this
review.
The Cochrane Renal Group’s Specialised Register contains studies
identified from:
1. Quarterly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL)
2. Weekly searches of MEDLINE OVID SP
3. Handsearching of renal-related journals and the proceedings of
major renal conferences
4. Searching of the current year of EMBASE OVID SP
5. Weekly current awareness alerts for selected renal journals
6. Searches of the International Clinical Trials Register (ICTRP)
Search Portal and ClinicalTrials.gov.
Studies contained in the specialised register are identified through
search strategies for CENTRAL, MEDLINE, and EMBASE based on
the scope of the Cochrane Renal Group. Details of these strategies,
as well as a list of handsearched journals, conference proceedings
and current awareness alerts, are available from the Specialised
Register section of information about the Cochrane Renal Group.
See Appendix 1 for search terms used in strategies for this review.
Data collection and analysis
This systematic review was originally undertaken by four authors
(GS, JC, EH, CJ) and was published in The Cochrane Database
of Systematic Reviews in 2005 (Strippoli 2005). This update was
undertaken by five authors (DO, AW, GS, KK, EH).
Selection of studies
Two authors independently screened titles and abstracts retrieved
from the searches and identified those studies that met the
inclusion criteria. This process favoured over-selection in order
to include all relevant studies. The full article was retrieved
if uncertainty existed or when the abstract was not available.
Any disagreement with article selection was resolved through
discussion and consultation.
Data extraction and management
Two authors independently extracted data from eligible studies
using standardised data extraction forms. Studies reported in
foreign language journals were translated before data extraction.
Participant characteristics (number, age, sex, co-morbidities),
interventions (type of treatment, dose, duration, co-interventions)
and primary and secondary outcome measures were recorded.
Authors were contacted to obtain missing information on allocation
concealment. Any discrepancies in data extraction were resolved
in discussion. Where results of a study were published more than
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once, the most complete data were extracted from all sources and
used in the analysis only once.
Assessment of risk of bias in included studies
The following items were independently assessed by two authors
using the risk of bias assessment tool (Higgins 2011; Appendix 2).
• Was there adequate sequence generation (selection bias)?• Was allocation adequately concealed (selection bias)?• Was knowledge of the allocated interventions adequately
prevented during the study (detection bias)?* Participants and personnel* Outcome assessors• Were incomplete outcome data adequately addressed (attrition
bias)?• Are reports of the study free of suggestion of selective outcome
reporting (reporting bias)?• Was the study apparently free of other problems that could put
it at a risk of bias?
Measures of treatment eKect
Dichotomous outcomes were expressed as risk ratios (RR) with
95% confidence intervals (CI). Risk diBerences (RD) with 95% CI
were calculated for adverse eBects. Continuous outcomes were
calculated as mean diBerences (MD) with 95% CI.
Unit of analysis issues
If available, data for the first period of cross-over studies were to
be included in meta-analyses; otherwise, cross-over studies were
reported in the text only.
Dealing with missing data
Study authors were contacted for information on sequence
generation, allocation concealments and for missing data. Where
missing data were few and not thought likely to influence results,
the available data were analysed.
Assessment of heterogeneity
Heterogeneity was analysed using a Chi2 test on N-1 degrees of
freedom, with an alpha of 0.05 used for statistical significance and
with the I2 test (Higgins 2003). I2 values of 25%, 50% and 75%
correspond to low, medium and high levels of heterogeneity.
Assessment of reporting biases
This updated review included all studies identified in the Cochrane
Renal Group's Specialised Register, which is revised regularly
with published and unpublished reports identified in congress
proceedings. This reduces the risk of publication bias. All reports
of a single study were reviewed to ensure that all outcomes were
reported to reduce the risk of selection bias.
Data synthesis
Data were pooled using a random-eBects model to calculate a
summary estimate of eBect.
Subgroup analysis and investigation of heterogeneity
To determine whether there was any diBerence between study
results due to plausible eBect modifiers, subgroup analysis was
planned provided that suBicient numbers of studies for analysis
were identified. The analysis aimed to explore the eBects of
patient characteristics such as type of solid organ transplanted,
type of intervention, dose and duration of intervention, level of
pre-existent risk, timing and methods used for diagnosis of CMV
infection, time to gra@ loss, HHV6/7 status, and quality of study on
treatment eBect.
Sensitivity analysis
Where a study's results diBered considerably from other studies in a
meta-analysis, exclusion of the study was investigated to determine
whether this altered the result of the meta-analysis.
R E S U L T S
Description of studies
Results of the search
The literature search for the original review consisted of a combined
search of MEDLINE, EMBASE, the Cochrane Central Registry of
Controlled Trials (CENTRAL) and the Cochrane Renal Group's
Specialised Register. There were 1930 articles identified. Of these,
1737 were excluded because they were not RCTs or were RCTs
that evaluated ineligible interventions. Full-text assessment of 193
potentially eligible articles identified 10 studies (14 reports; 476
participants) (Brennan 1997a Kidney; Jung 2001 Kidney; Koetz
2001 Kidney; Paya 2002 Liver; Queiroga 2003 Kidney; Rayes 2001
Liver; Sagedal 2003 Kidney; Singh 2000 Liver; Singh 1994 Liver;
Yang 1998 Kidney). Four study authors responded to queries about
uncertainties on study methods (Brennan 1997a Kidney; Jung 2001
Kidney; Singh 2000 Liver; Singh 1994 Liver).
For this update, only the Cochrane Renal Group's Specialised
Register was searched. This is updated continuously and contains
all new kidney and related studies, reports and articles. The search
identified 20 reports of nine studies. Of the nine studies, five were
new studies of pre-emptive therapy versus prophylaxis (Gerna
2008 Liver; Khoury 2006 Kidney; Kliem 2008 Kidney; Reischig 2008
Kidney; Witzke 2012 Kidney). Two additional reports were identified
in the search but had already been included in the original review
(Singh 1998; Yang 1996). A further two studies (Qiu 2008 Kidney;
Tian 2005 Kidney) were identified from a systematic review of RCTs
conducted by Zhang 2011. Further assessment of these studies,
including contact with the authors facilitated through the Chinese
Cochrane Centre, indicated that participants were not randomised,
hence these studies were excluded. One study author responded
to queries about uncertainties on study methods (Khoury 2006
Kidney).
There are three ongoing studies that are potentially relevant to
this review (NCT00372229; NCT00966836; NCT01552369). When
concluded these studies will be assessed for inclusion in a future
update of this review. Another study relevant to this review was
also identified for inclusion (Scott 2011 Liver), however, more
information has been requested from the authors before the study
can be included in meta analysis.
The combined search results are presented in Figure 1.
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Figure 1.   Combined search results for the original and updated reviews. Reasons for exclusions are provided in text
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Figure 1.   (Continued)
 
Included studies
The combined updated study data included 1098 participants from
15 studies. Three intervention rationales were investigated by these
studies.
One rationale involved randomising participants at transplant
to receive viral surveillance and pre-emptive treatment on
development of CMV viraemia versus prophylaxis with antiviral
medications for 30 to 168 days (8 studies, 785 participants: Gerna
2008 Liver; Jung 2001 Kidney; Khoury 2006 Kidney; Kliem 2008
Kidney; Queiroga 2003 Kidney; Reischig 2008 Kidney; Singh 1994
Liver; Witzke 2012 Kidney). (This was the only rationale in previous
iterations of this review to which new study data were added for
this update).
A second rationale involved randomising participants to pre-
emptive treatment or to placebo or no specific therapy (6
studies, 291 participants: Brennan 1997a Kidney; Koetz 2001
Kidney; Paya 2002 Liver; Rayes 2001 Liver; Sagedal 2003 Kidney;
Yang 1998 Kidney). In five of these studies (Koetz 2001 Kidney;
Paya 2002 Liver; Rayes 2001 Liver; Sagedal 2003 Kidney; Yang
1998 Kidney), all transplant recipients were screened for CMV
viraemia. Study participants who developed viraemia were then
randomised to receive pre-emptive treatment or placebo/standard
care. In the study by Brennan 1997a Kidney, transplant recipients
were randomised at transplant to receive pre-emptive treatment
(screening and treatment of those with positive viraemia) or
standard care (treatment of symptomatic CMV infection when it
developed). Screening occurred at the time of transplantation and
at weekly intervals therea@er.
The third rational type was applied in a study by Singh 2000
Liver. It investigated 22 patients who developed CMV viraemia, and
were randomised to receive oral or intravenous ganciclovir as pre-
emptive treatment.
All studies investigated ganciclovir or valganciclovir. Six studies
compared ganciclovir with placebo or delayed treatment (Brennan
1997a Kidney; Koetz 2001 Kidney; Paya 2002 Liver; Rayes 2001
Liver; Sagedal 2003 Kidney; Yang 1998 Kidney); five compared
pre-emptive ganciclovir with prophylactic ganciclovir (Gerna 2008
Liver; Jung 2001 Kidney; Kliem 2008 Kidney; Queiroga 2003 Kidney;
Singh 2000 Liver); two compared pre-emptive valganciclovir with
prophylactic valganciclovir (Khoury 2006 Kidney; Witzke 2012
Kidney); one study compared pre-emptive valganciclovir with
prophylactic valaciclovir (Reischig 2008 Kidney); and one compared
pre-emptive ganciclovir with prophylactic aciclovir (Singh 1994
Liver).
Follow-up duration of all studies ranged from three to 18 months.
Excluded studies
Overall, we excluded 1976 studies. The 2005 review excluded 1916
reports, 33 reports were assessed and excluded in 2010, and
27 reports in this update. Most exclusions were made following
assessment of title and abstract appraisal. The most common
reasons for exclusion were for non-randomisation of participants or
were for RCTs that investigated interventions outside the inclusion
criteria for this review.
Risk of bias in included studies
Assessing risk of bias was problematic because many details were
diBicult to ascertain or not provided (see Characteristics of included
studies). Study authors were contacted for clarification of study
outcomes where reporting was inadequate (see Figure 2; Figure 3).
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Figure 2.   Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies
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Figure 3.   Risk of bias summary: review authors' judgements about each risk of bias item for each included study
 
 
Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
14
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Figure 3.   (Continued)
 
Allocation
Allocation concealment was considered to be at low risk of bias in
four studies (Khoury 2006 Kidney; Kliem 2008 Kidney; Paya 2002
Liver; Witzke 2012 Kidney); while the remaining studies did not
report methods used to conceal the randomisation process.
Risk of bias in random sequence generation bias was considered
low in five studies (Khoury 2006 Kidney; Kliem 2008 Kidney; Paya
2002 Liver; Reischig 2008 Kidney; Singh 1994 Liver). While the
majority of other papers reported randomisation of patients, the
method used to generate a random sequence was not reported. The
risk of bias in random sequence generation was high in one study
(Brennan 1997a Kidney) (last digit of medical number).
Blinding
Blinding of participants and personnel was reported in Koetz
2001 Kidney and Paya 2002 Liver. However, only Paya 2002 Liver
provided detailed information to indicate that the study was at
low risk of performance bias. Neither study reported blinding or
provided information on whether outcome assessors were blinded
to intervention groups. Of the 15 included studies, five (Gerna
2008 Liver; Kliem 2008 Kidney; Reischig 2008 Kidney; Sagedal 2003
Kidney; Witzke 2012 Kidney) were reported to be open-label. These,
and the remaining eight studies, were assessed as being at high risk
of bias for performance and detection bias because interpretation
of the clinical outcome of CMV disease by clinical features could
be aBected by lack of blinding of participants, investigators and
outcome assessors.
Incomplete outcome data
Brennan 1997a Kidney had missing outcome data due to losses
to follow-up. However, this was considered unlikely to influence
the results of this study. Bias due to incomplete outcome data was
considered low for all other studies.
Selective reporting
Bias through selective reporting was considered a low risk in eight
studies (Brennan 1997a Kidney; Jung 2001 Kidney; Khoury 2006
Kidney; Kliem 2008 Kidney; Rayes 2001 Liver; Reischig 2008 Kidney;
Sagedal 2003 Kidney; Witzke 2012 Kidney). In the remaining seven,
selective reporting bias was considered high as they did not report
outcomes of importance for this review. In the study of Gerna 2008
Liver gra@ loss, adverse eBects and opportunistic infections were
not reported. In the studies by Koetz 2001 Kidney and Yang 1998
Kidney all-cause mortality, gra@ loss and acute rejection were not
reported. In Paya 2002 Liver, all-cause mortality and gra@ loss were
not reported. Acute rejection was not reported in either Queiroga
2003 Kidney or Singh 1994 Liver, and Singh 2000 Liver did not report
gra@ loss or acute rejection.
Other potential sources of bias
Five studies reported pharmaceutical sponsorship (Khoury 2006
Kidney; Kliem 2008 Kidney; Paya 2002 Liver; Sagedal 2003 Kidney;
Witzke 2012 Kidney) and were judged as high risk of bias.
Several other studies reported sponsorship from educational and
government organisations (Brennan 1997a Kidney; Gerna 2008
Liver; Reischig 2008 Kidney; Yang 1998 Kidney). These studies were
considered to be at low risk of bias. The remaining studies did not
state any form of sponsorship and their risk of bias was unclear
(Jung 2001 Kidney; Koetz 2001 Kidney; Queiroga 2003 Kidney;
Rayes 2001 Liver; Singh 1994 Liver; Singh 2000 Liver).
EKects of interventions
See: Summary of findings for the main comparison Pre-emptive
medication for cytomegalovirus (CMV) viraemia compared to
placebo/no treatment to prevent CMV disease in solid organ
transplant recipients; Summary of findings 2 Pre-emptive
medication compared to prophylaxis for cytomegalovirus (CMV)
viraemia to prevent CMV disease in solid organ transplant recipients
Pre-emptive treatment for CMV infection versus placebo or
standard care
There were 1393 patients screened for entry to the six studies of
pre-emptive treatment versus placebo or standard care. Of these,
1035 patients were excluded (no CMV viraemia in 597, CMV viraemia
below threshold for study entry in 116, other reasons in 322) so
that 358 patients were eligible for study entry. However, 64 patients
(17.8%) developed CMV disease within the 0 to 10 day time gap
between testing for viraemia and randomisation, and thus were
excluded. The proportion of patients in each study who developed
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CMV disease before CMV viraemia was detected varied from 0%
to 32%. In addition, six (1.7%) other patients were excluded a@er
randomisation for protocol violations, so that 288 patients were
evaluated.
Compared with placebo or standard care, pre-emptive treatment
significantly reduced the risk of CMV disease (Analysis 1.1 (6
studies, 288 participants): RR 0.29, 95% CI 0.11 to 0.80). The
heterogeneity (I2 = 54%, P = 0.06) was explained by the study
undertaken by Brennan 1997a Kidney, which was the only study in
which transplant recipients were randomised to screen (and treat)
for CMV viraemia versus no screening, rather than randomising
participants with CMV viraemia to treatment or not. Removing this
study resulted in homogenous results (I2 = 0%, P = 0.54). There
was no significant diBerence for the outcome of CMV disease in
studies that used oral ganciclovir compared with studies that used
intravenous ganciclovir preparations (P = 0.93 for interaction).
For the outcomes of CMV organ involvement (Analysis 1.2 (5 studies,
217 participants): RR 0.41, 95% CI 0.06 to 2.63) or CMV associated
symptoms (Analysis 1.3 (5 studies, 217 participants): RR 0.28, 95%
CI 0.06 to 1.21), the summary estimates favoured treatment, but
the CIs were wide. There was also no significant diBerence in the
risks of acute rejection (Analysis 1.4 (3 studies, 185 participants):
RR 1.21, 95% CI 0.69 to 2.12), all-cause mortality (Analysis 1.5.1
(3 studies, 176 participants): RR 1.23, 95% CI 0.35 to 4.30), gra@
loss (Analysis 1.5.2 (1 study, 36 participants): 0.28, 95% CI 0.01 to
5.35), leucopenia (Analysis 1.7.1 (2 studies, 114 participants): RR
1.54, 95% CI 0.16 to 15.36), or kidney dysfunction (Analysis 1.7.2
(1 study, 36 participants): RR 0.93, 95% CI 0.18 to 4.92). There was
no significant variation in treatment eBect for any these outcomes
when studies that used oral and intravenous ganciclovir regimens
were considered separately.
Pre-emptive treatment for CMV viraemia versus anti-viral
prophylaxis
Symptomatic CMV disease occurred at rates between 0% and 28.7%
in the pre-emptive group and 0% and 29.2% in the prophylaxis
group. The risk of developing CMV disease was not significantly
diBerent among groups (Analysis 2.1 (7 studies, 753 participants):
RR 1.02; 95% CI 0.43 to 2.44).
There was considerable heterogeneity among the seven studies
(I2 = 67%). Of these, two favoured pre-emptive therapy and two
favoured prophylaxis. Removal of studies by Khoury 2006 Kidney
and Singh 1994 Liver from the analysis, which both favoured
pre-emptive therapy, decreased heterogeneity considerably (I2 =
26%) and a clinically significant result favouring prophylaxis was
observed (5 studies, 608 participants: RR 2.19, 95% CI 1.3 to 4.23).
Investigation of the Singh 1994 Liver study indicated that an inferior
agent (aciclovir) was used in the prophylaxis arm compared with a
superior agent (ganciclovir) in the pre-emptive arm (Hodson 2013)
which may have exerted a favourable influence on pre-emptive
treatment. Investigation of the Khoury 2006 Kidney study did not
yield any substantial diBerences to account for the reduction in
heterogeneity.
It was found that alternately excluding the two studies (Kliem 2008
Kidney; Witzke 2012 Kidney) that favoured prophylaxis, the relative
risk supported pre-emptive therapy, although the result was not
significant (5 studies, 319 participants: RR 0.42; 95% CI 0.16 to 1.11).
CMV infection was significantly more common in the pre-emptive
group compared with the prophylaxis group (Analysis 2.2 (7 studies,
727 participants): RR 2.06, 95% CI 1.44 to 2.96). However, there was
considerable heterogeneity (12 = 71%).
There was no significant diBerence observed between the pre-
emptive and prophylaxis groups for all-cause mortality (Analysis
2.3.1 (7 studies, 753 participants): RR 1.19, 95% CI 0.56 to 2.51),
gra@ loss (Analysis 2.3.2 (7 studies, 753 participants): RR 1.07,
95% CI 0.41 to 2.82), and acute rejection (Analysis 2.4 (6 studies,
693 participants): RR 1.23, 95% CI 0.75 to 2.03). No heterogeneity
existed among the studies for all-cause mortality. Some degree
of heterogeneity existed in the gra@ loss analysis (I2 = 41%) and
acute rejection (I2 = 44%) analyses. Heterogeneity was considerably
diminished (I2 = 14%) in the gra@ loss analysis when Jung 2001
Kidney was excluded. The only diBerences observed between Jung
2001 Kidney and all other studies were a later start for prophylaxis
and a higher dose of oral ganciclovir (3000 mg/d compared with
1500 mg to 2000 mg/d).
Heterogeneity was abolished entirely in the acute rejection analysis
when the study by Witzke 2012 Kidney was excluded from the
analysis. The only diBerence that existed between the Witzke
2012 Kidney study and others was the non-inclusion of high risk
transplant recipients (D+/R-).
No significant diBerence was identified between pre-emptive
therapy and prophylaxis for infections other than CMV including
bacterial (Analysis 2.5.1 (2 studies, 168 participants): RR 0.89, 95%
CI 0.55 to 1.43), viral (Analysis 2.5.2 (1 study, 70 participants): RR
1.57, 95% CI 0.92 to 2.70), and fungal infections (Analysis 2.5.3 (1
study, 70 participants): RR 1.89, 95% CI 0.18 to 19.89).
Leucopenia was significantly less common in patients who
underwent pre-emptive therapy compared with prophylaxis
(Analysis 2.6.1 (6 studies, 729 participants): RR 0.42, 95% CI 0.20
to 0.90). Some heterogeneity existed among the studies (I2 = 45%)
which was considerably diminished when the Kliem 2008 Kidney
study was excluded from the analysis (I2 = 15%). No identifiable
diBerences in the Kliem 2008 Kidney study were observed in
comparison with others in this subgroup analysis. No significant
diBerence was observed for neurological dysfunction between the
therapies (Analysis 2.6.2 (3 studies, 187 participants): RR 0.58, 95%
CI 0.17 to 1.96).
In general, other adverse eBects were poorly reported in eight pre-
emptive therapy versus prophylaxis studies; one study (Reischig
2008 Kidney) provided most of the data (Analysis 2.6).
Serostatus stratification of CMV disease was reported in two
studies (Khoury 2006 Kidney; Reischig 2008 Kidney). No significant
diBerences in symptomatic CMV disease or CMV infection were
observed between pre-emptive treatment and prophylaxis for
high risk transplant recipients (D+/R-) (Analysis 2.7). For lower
risk transplant recipients (D+ or D-/R+), there was no significant
diBerence in symptomatic CMV disease (Analysis 2.8.1) but CMV
infection was significantly less common in recipients receiving
prophylaxis (Analysis 2.8.2 (2 studies, 129 participants): RR 2.07,
95% CI 1.25 to 3.42).
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Oral versus intravenous ganciclovir for pre-emptive treatment
of CMV viraemia
We found that 22/72 (31%) liver transplant recipients undergoing
surveillance developed CMV viraemia and entered a study
comparing oral and intravenous ganciclovir for pre-emptive
treatment (Singh 2000 Liver). There were no significant diBerences
in the risk of CMV disease (Analysis 3.1), all-cause mortality
(Analysis 3.2) or other infections (Analysis 3.3) between the
regimens.
Other outcomes
No data were available on the outcomes of death due to CMV
disease. The time to development of CMV disease outcome was
reported in four studies (Gerna 2008 Liver; Khoury 2006 Kidney;
Kliem 2008 Kidney; Reischig 2008 Kidney). Moreover, the diBerent
methods of measurement used to report these outcomes (median,
mean and frequencies) prevented meta-analysis.
Subgroup analyses according to organ transplanted, antiviral
medication, duration of treatment, timing and methods used for
diagnosis of CMV infection, time to gra@ loss, HHV6/7 status or
methodological quality were not possible because of the small
number of studies and enrolled patients.
D I S C U S S I O N
Summary of main results
This review identified eight studies that compared pre-emptive
with prophylactic therapy (784 patients) and six studies that
compared pre-emptive therapy versus placebo or standard care
(288 patients) where the primary outcome was CMV disease. Tests
and thresholds used to detect CMV viraemia were diBerent across
the studies, but results were generally consistent. Confidence
intervals were wide across most outcomes, indicating considerable
imprecision (Summary of findings for the main comparison;
Summary of findings 2). Fewer patients were evaluated for other
outcomes, and CIs around observed treatment eBects were so wide
that other benefits (or harms) of pre-emptive therapy could not be
excluded.
Pre-emptive treatment using standard detection methods for CMV
viraemia was 71% more eBective than placebo or standard care
in reducing the risk of CMV disease (RR 0.29, 95% CI 0.11 to
0.80). CMV organ involvement was 59% lower in the pre-emptive
therapy regime compared with the placebo/standard care regime.
However, the quality of evidence was low due to small patient
numbers and lack of blinding across all studies. No significant
diBerences in the risks of all-cause mortality, acute rejection,
gra@ loss, other infections, leucopenia, or kidney dysfunction
were demonstrated between pre-emptive therapy and placebo or
standard care (Summary of findings for the main comparison).
There was no significant diBerence in preventing CMV disease
using pre-emptive versus prophylactic therapy. However, there
was significant heterogeneity among studies so that superiority
of one or other treatment could not be excluded. The major
benefit observed for pre-emptive therapy was a 58% reduction in
leucopenia compared with prophylaxis, while other adverse eBects
did not diBer significantly, or were not reported. There were no
significant diBerences in the risks of all-cause mortality, gra@ loss,
acute rejection and infections other than CMV. There was also no
significant diBerence observed between pre-emptive therapy and
prophylaxis with regards to CMV disease in high risk solid organ
transplant patients (D+/R-) (Summary of findings 2).
Only one study of oral versus IV pre-emptive regimens was included
in this review; it showed no significant diBerence in the risk of CMV
disease between the groups.
It should be emphasised that oral ganciclovir, which was the basis
for three of the included analyses, is no longer available and has
been replaced by valganciclovir.
Overall completeness and applicability of evidence
Overall, the evidence from the 15 studies included in this review
prevented confident conclusions to be made on the eBicacy of
pre-emptive therapy in preventing CMV disease, gra@ loss, acute
rejection and all-cause mortality in comparison with placebo/no
specific treatment or with prophylaxis. This was primarily due
to a lack of adequately powered studies and low precision of
the measured outcomes. There was also a lack of studies that
compared pre-emptive therapy across a broad range of diBerent
transplanted organs; the highest representation was for kidney
transplant recipients among the 15 studies included in this review.
Many studies did not address important outcomes, including
adverse eBects of medications. In contrast, the evidence base for
routine prophylaxis compared with placebo/no specific therapy is
substantial, arising from 19 studies of 1981 participants (Hodson
2005; Hodson 2013) which enabled more precise results to be
derived.
Prophylaxis has been shown to reduce CMV disease by about
60% (RR = 0.42), with tight CIs (0.34 to 0.52), strong evidence
of statistically significant benefit (P < 0.0001), and considerable
homogeneity of results across all studies (I2 = 13%, where only one
of the point estimates of the 19 studies did not favour prophylaxis
(Hodson 2005; Hodson 2013).
Antiviral prophylaxis has been shown to reduce CMV-related
mortality, all-cause mortality, and clinically important disease
caused by opportunistic infections.
Although both prophylaxis (Hodson 2013) and pre-emptive therapy
significantly reduce CMV disease compared with placebo or no
specific therapy in solid organ transplant recipients, this review
has demonstrated that the available data evaluating pre-emptive
therapy (6 studies; 288 participants) was of low quality (GRADE)
compared with the high quality data (GRADE) evaluating antiviral
prophylaxis (19 studies; 1981 participants).
There appeared to be little evidence that the use of medications
now considered to be less eBective than valganciclovir or
ganciclovir (Humar 2009; Pescovitz 2007) influenced the results
in studies comparing pre-emptive therapy with prophylaxis. Two
studies (117 participants) of eight studies used aciclovir (Singh 1994
Liver) or valaciclovir (Reischig 2008 Kidney) in the prophylaxis arm
of the studies. This would potentially favour pre-emptive therapy
and could have contributed to the results of the Singh 1994 Liver
study. All studies comparing pre-emptive therapy with placebo or
no specific therapy used ganciclovir, which has been superseded
by valganciclovir for prophylaxis or pre-emptive therapy. RCT data
have shown no significant diBerence in eBicacy for prophylaxis
of CMV disease between ganciclovir and valganciclovir (Hodson
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2005) so it can be presumed that valganciclovir would be more
eBective than placebo in prophylaxis or pre-emptive therapy
studies, although this has not been formally tested in RCTs.
There was also substantial diBerence among studies with regard to
CMV surveillance testing. The type of test used (pp65 antigenaemia
assay or PCR DNA), the assays used, the frequency of surveillance
(weekly to monthly), the cut-oB values (DNA PCR > 400 to > 2000
copies/mL) to define CMV infection and the blood component used
for testing were factors contributing to these diBerences. This large
variability among studies further reduced confidence of drawing
definite conclusions about the applicability of pre-emptive therapy
for several reasons. Longer time intervals between surveillance
tests potentially increases the chances of CMV infection not being
detected so that the patient develops CMV disease before he or
she can be entered in a study. This means that the proportion of
preventable CMV disease patients in the pre-emptive arm may have
erroneously increased. Lower cut-oB values used for diagnosing
CMV infection with more frequent testing could result in earlier
detection of CMV infection and enable earlier initiation of therapy
to prevent CMV disease and reduce the eBects of indirect CMV
infection. Alternatively, higher cut-oB values with longer periods
between tests could result in delayed therapy and potentially
increase the number of preventable CMV disease cases. Finally,
PCR testing needs consideration as to what component of blood is
being tested; whole blood will o@en yield higher rates of CMV DNA
compared to plasma (Humar 2009).
Quality of the evidence
This systematic review identified 15 studies of 1094 participants;
of these, 784 participants were evaluated in studies that compared
pre-emptive therapy with prophylaxis; and 288 were evaluated
in studies that compared pre-emptive therapy with placebo/no
specific treatment. The 15 studies failed to report all relevant
outcomes, were frequently at high risk of bias, demonstrated
imprecision and heterogeneity among studies which lowered the
integrity of the meta-analysed results.
The poorly reported methods of randomisation and allocation
concealment have prevented an accurate assessment of the
risk of selection bias: only three studies adequately performed
both. The lack of allocation concealment in these studies
introduced the potential to overestimate outcome benefits (Hewitt
2005). The blinding of outcome assessors and personnel was
poorly performed in most studies; only one reported blinding of
participants and investigators. The blinding of outcome assessors
was not conducted in any study because all study authors were
judged to also be outcome assessors. Therefore, most included
studies were at high risk of both performance and detection bias.
The risk of attrition bias was considered to be low in all studies. Half
of the studies did not include outcomes that were assessed to be
important by the review authors.
Pre-emptive therapy compared with placebo/no specific therapy
significantly reduced CMV disease (RR 0.29, 95% CI 0.11 to 0.80).
However, CIs were wide (0.11 to 0.80), statistical significance
was moderate (P = 0.02), and there was evidence of significant
heterogeneity among studies (I2 = 54%): two studies favoured
pre-emptive therapy and two large studies favoured prophylaxis.
Similarly, no significant diBerence was identified in the risk for
CMV disease between pre-emptive therapy and prophylaxis (RR
1.02, 95% CI 0.43 to 2.44); CIs were wide, indicating considerable
imprecision, and there was significant heterogeneity (I2 = 63%).
Data for outcomes other than CMV disease were more limited.
Particularly, we found that there was failure to report outcomes
relating to adverse eBects. We also found that low participant
numbers and few events increased imprecision.
Only two studies stratified CMV disease and infection by the high
risk serostatus D+/R- (Khoury 2006 Kidney; Reischig 2008 Kidney).
Only 49 patients were available from these two studies which
prevented comprehensive analysis. Such subset analysis required
a larger sample size to enable accurate assessment of this high risk
group.
Overall, the quality of the evidence was considered to be low or
very low because of small numbers of enrolled participants, few
events, significant heterogeneity, lack of blinding, and inadequate
allocation concealment (Summary of findings for the main
comparison; Summary of findings 2).
Potential biases in the review process
The search criteria, analysis, and data extraction were performed
to a high standard (see Methods). Four reviewers independently
performed the analysis and data extraction; any conflict was
resolved by an independent party. This further decreased the
risk of bias for the review. The search strategy for the review
was thorough. The Cochrane Renal Group's Specialised Register
includes complete listings of current studies and is regularly
updated to include new studies and additional reports of existing
studies from journals and conference reports.
It is possible that some studies may have been missed where the
study report has only been published in abstract form in conference
proceedings, which have not yet been handsearched.
Overall, this review and review search represent an up-to-date
assessment of current pre-emptive therapy studies.
Agreements and disagreements with other studies or
reviews
Zhang 2011 conducted a systematic review comparing pre-emptive
therapy and prophylaxis in solid organ transplants, and consistent
with our review findings, also found no significant diBerence in
the risk of CMV disease, gra@ loss, acute rejection and mortality
between pre-emptive therapy and prophylaxis. However, our
review identified a 58% reduced risk of leucopenia in the pre-
emptive therapy rationale which was not identified by Zhang 2011.
The studies included in this review for pre-emptive treatment
versus prophylaxis were mostly the same as those analysed by
Zhang 2011; the exceptions were two Chinese studies included by
Zhang 2011 that were excluded from our review on the basis that
they were not RCTs (Qiu 2008 Kidney; Tian 2005 Kidney). Zhang
2011 did not include either the Gerna 2008 Liver transplant study
in children or the liver transplant study by Singh 1994 Liver which
were included in this review. This would account for numerical
variations between these reviews, although much of the statistical
outcomes remain the same.
A recent commentary on CMV in solid organ transplant recipients
also suggested the need for more studies comparing pre-emptive
therapy with prophylaxis to identify if pre-emptive therapy may
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increase the risk of the indirect eBects of CMV infection (Humar
2009). This is in agreement with our findings where several
studies did not report on outcomes relating to indirect eBects of
CMV infection. Our findings are consistent with recent guidelines
from the British Transplantation Society (BTS 2011), Kidney
Disease Improving Global Outcomes (KDIGO 2009) and Caring for
Australians with Renal Impairment (CARI 2010). A summary of these
guidelines are presented in Table 1.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
This systematic review identified no significant diBerences
in eBicacy between pre-emptive therapy and prophylaxis for
preventing CMV disease, gra@ loss, and death in solid organ
transplant recipients. However, study data remain sparse. The
ability to ascertain true benefits and harms remains problematic
when compared with prophylaxis due to heterogeneity between
study results together with low sample sizes and event rates leading
to imprecision.
Pre-emptive therapy has shown benefits over placebo and
standard care. This review has identified an increased risk
of CMV infection with pre-emptive therapy, which may have
deleterious impacts on the indirect eBects of CMV infection
including gra@ loss, acute rejection, and infections other than
CMV compared with prophylaxis. While no significant diBerences
in meta-analyses could be demonstrated for these outcomes,
heterogeneity around the results indicate that diBerences cannot
be excluded. Furthermore, four year follow-up data reported by
Reischig 2008 Kidney suggest that gra@ loss may be higher in
patients treated with prophylaxis compared with pre-emptive
therapy. Four year follow-up data for the much larger Witzke 2012
Kidney study are awaited.
This review highlights the need to standardise testing frequency
and cut oB levels for positive tests used in the surveillance
testing for CMV infection which could reduce variability between
institutions and in studies. A standardised method should test
patients frequently (especially within the first six months post-
transplant) and should have a low threshold for detection. The
results should be immediately available to enable therapy to be
commenced as soon as possible a@er the surveillance threshold is
exceeded.
Implications for research
In view of the heterogeneity of results in currently available
studies, further well designed and adequately powered studies
are required to compare three or more months of prophylactic
therapy using an anti-CMV viral medication with pre-emptive
therapy for patients who develop viraemia. Such studies should be
powered to enable assessment of direct and indirect eBects of CMV
infection, adverse eBects of medications and resource utilisation
have suBicient follow-up to assess gra@ loss and mortality, and
include standardised thresholds and frequency of testing for CMV
viraemia.
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Methods • Study design: parallel RCT• Follow-up period: 12.3 to 18.2 months
Participants • Country: USA• Setting: University• CMV status: D/R+; D+/R-• Kidney transplant recipients: 1st transplant (48); 2nd transplant (3)• Number: 39• Mean age ± SD: treatment group (48 ± 2.6 years); control group (47 ± 3.2 years)
Interventions Treatment group
• Pre-emptive IV ganciclovir 5 mg/kg every 12 hours for 3 weeks
Control group
• Deferred ganciclovir (same schedule)
Outcomes 1. CMV disease
2. Acute rejection
3. All-cause mortality
4. Gra@ loss
5. Adverse events
Notes • Method for detection of CMV infection: qualitative PCR for CMV DNA; shell vial culture; serology
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomisation reported but method not specified
Brennan 1997a Kidney 
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Allocation concealment
(selection bias)
High risk Authors reported that patients allocated according to last digit of medical
record number (odd and even numbers)
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Not blinded as some patients received IV medications while other received
no treatment. The interpretation of clinical symptoms could be influenced by
blinding
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Outcome analysis was likely performed by the study investigators.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 3 patients excluded but this was unlikely to influence results
Selective reporting (re-
porting bias)
Low risk All outcomes specified in methods are reported
Other bias Low risk Supported by grant from Missouri Kidney Program
Brennan 1997a Kidney  (Continued)
 
 
Methods • Study design: parallel RCT• Follow-up period: 24 months
Participants • Country: Italy• Setting: NS• CMV status: D+/R+, D+/R-• Paediatric liver transplant patients• Number: 21• Median age; range: treatment group (11 months; 2 months to 11 years); control group (19 months; 6
months to 6 years)
Interventions Treatment group
• Pre-emptive ganciclovir 5 mg/kg twice/d when positive CMV DNAemia occurred
Control group
• Prophylactic ganciclovir 5 mg/kg twice/d for 30 days then pre-emptive IV ganciclovir 5 mg/kg twice/
d when positive CMV DNAemia occurred
Outcomes 1. CMV infection
2. Acute rejection
3. Time to development of CMV
Notes • Method for detection of CMV infection: qualitative PCR for CMV DNA >100,000 copies/mL for pre-emp-
tive therapy; viral assay pp65-antigenaemia for prophylaxis
Risk of bias
Bias Authors' judgement Support for judgement
Gerna 2008 Liver 
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Random sequence genera-
tion (selection bias)
Unclear risk Randomisation reported but method not specified
Allocation concealment
(selection bias)
Unclear risk Authors did not report method used to conceal allocation of patients
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open labelled and the interpretation of clinical symptoms could be influenced
by blinding
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Outcome was likely dependent on the study investigators as the study was
open labelled.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk No missing data
Selective reporting (re-
porting bias)
High risk All outcomes specified in methods were reported; however, outcomes of inter-
est were not reported: gra@ loss, gra@ function, adverse effects of medications
and other infections
Other bias Low risk Trial stopped early due to ethical reasons. No significant difference between
the groups led to the conclusion that prophylactic treatment of patients would
be unethical due to unjustified treatment.
Gerna 2008 Liver  (Continued)
 
 
Methods • Study design: parallel RCT• Follow-up period: 12 months
Participants • Country: Germany• Setting: NS• CMV status: D/R+, D+/R-, D-/R-• Kidney transplant recipients (1st transplant only)• Number: 70• Mean age: NS
Interventions Treatment group
• Pre-emptive oral ganciclovir 3000 mg/d for 14 days or until test negative
Control group
• Prophylactic oral ganciclovir 3000 mg/d for 90 days starting at week 2 after transplant
Outcomes 1. CMV disease
2. CMV infection
3. Acute rejection
4. All-cause mortality
5. Gra@ loss
6. Adverse events
Jung 2001 Kidney 
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Notes • Method for detection of CMV infection: pp65 antigenaemia > 2 positive cell/20 x 104; PCR for CMV DNA
> 400 copies/mL5
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomisation reported but method not specified
Allocation concealment
(selection bias)
Unclear risk Authors did not report method used to conceal allocation of patients
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Not blinded as no placebo was given to the pre-emptive group. The interpreta-
tion of clinical symptoms could be influenced by blinding
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Outcome analysis was likely performed by the study investigators and assess-
ment of the outcome could be influenced by lack of blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk No missing data
Selective reporting (re-
porting bias)
Low risk All outcomes specified in methods are reported
Other bias Unclear risk No sponsorship of trial was stated
Jung 2001 Kidney  (Continued)
 
 
Methods • Study design: parallel RCT• Follow-up period: 12 months
Participants • Country: USA• Setting: University• CMV status: D/R+, D+/R-, D-/R-• Kidney transplant recipients• Number: 99• Mean age ± SD: treatment group (47.5 ± 14.96 years); control group (51.9 ± 13.91 years)
Interventions Treatment group
• Pre-emptive oral valganciclovir 900 mg twice/d for at least 21 days or until test negative
Control group
• Prophylactic oral valganciclovir 900 mg/d for 100 days after transplantation
Outcomes 1. CMV disease
2. CMV infection
3. All-cause mortality
4. Gra@ loss
Khoury 2006 Kidney 
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5. Other infections
6. Acute rejection
7. Pharmacoeconomics
8. Time to development of CMV
Notes • Method for detection of CMV infection: quantitative PCR on whole blood for CMV DNAemia with a cut
oB value of > 2000 copies/mL
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomised by computer program with 1:1 block design
Allocation concealment
(selection bias)
Low risk Clinical pharmacist allocation
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Not blinded as pre-emptive group was not given placebo. The interpretation of
clinical symptoms could be influenced by blinding
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Outcome analysis was likely performed by the study investigators
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk No missing data
Selective reporting (re-
porting bias)
Low risk All outcomes specified in methods are reported and all outcomes of impor-
tance were included
Other bias High risk Roche supplied research support and the antiviral medication
Khoury 2006 Kidney  (Continued)
 
 
Methods • Study design: parallel RCT• Follow-up period: 48 months
Participants • Country: Germany• Setting: Multicentre• CMV status: D/R+, D+/R-, D-/R-• Kidney transplant recipients• Number: 148• Mean age ± SD: treatment group (50.9 ± 12.4 years); control group (48.3 ± 12.4 years)
Interventions Treatment group
• Pre-emptive IV ganciclovir 5 mg/kg twice/d for at least 10 days or until test was < 100 copies CMV DNA/
mL on two successive tests
Control group
Kliem 2008 Kidney 
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• Prophylactic oral ganciclovir 1000 mg/d for 90 days within 48 hours following transplantation (for
those who could not tolerate oral therapy temporary prophylaxis was provided as ganciclovir 5 mg/
kg twice daily)
Outcomes 1. CMV disease
2. CMV infection
3. All-cause mortality
4. Gra@ loss
5. Acute rejection
6. Gra@ function
7. Adverse events
8. Time to development of CMV
Notes • Method for detection of CMV infection: quantitative PCR on whole blood for CMV DNAemia with a cut
oB value of > 400 copies/mL
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomised to either treatment group centrally by phone
Allocation concealment
(selection bias)
Low risk Central allocation
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open labelled. The interpretation of clinical symptoms could be influenced by
blinding.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Outcome analysis was likely performed by the study investigators
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk No missing data
Selective reporting (re-
porting bias)
Low risk All outcomes specified in methods are reported, however, outcome of infec-
tions not reported, however, it is unlikely that this would affect study outcome
Other bias High risk Support from Roche Pharma AG
Authors; Kliem, Fricke, Burg and Radermacher received honoraria for speaking
and providing advice to Roche Pharma AG
Kliem 2008 Kidney  (Continued)
 
 
Methods • Study design: parallel RCT• Follow-up period: 3 months
Participants • Country: Germany• Setting: University• CMV status: D/R+, D+/R-
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• Kidney and liver transplant recipients• Number: 12• Mean age: NS
Interventions Treatment group
• Pre-emptive IV ganciclovir 2 x 5 mg/kg/d for 2 weeks
Control group
• Placebo: 0.9% NaCl for 2 weeks
Outcomes 1. CMV disease and syndrome
Notes • Method for detection of CMV infection: pp65 antigenaemia > 5 positive cells/20 x 104
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomisation reported but method not specified
Allocation concealment
(selection bias)
Unclear risk Authors did not report method used to conceal allocation of patients
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Authors reported study as double blind but did not state methods
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not reported and unclear whether outcome assessors were blinded to treat-
ment groups
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk No missing data
Selective reporting (re-
porting bias)
High risk All outcomes specified in methods were reported; however, outcomes of inter-
est not reported included death, gra@ loss, gra@ function and acute rejection
Other bias Unclear risk No sponsorship of trial was stated
Koetz 2001 Kidney  (Continued)
 
 
Methods • Study design: parallel RCT• Follow-up period: 4 months
Participants • Country: USA• Setting: University• CMV status: D/R+, D+/R-• Liver transplant recipients (1st transplant only)• Number: 69• Median age; range: treatment group (54 years; 23 to 67 years); control group (50 years; 26 to 67 years)
Paya 2002 Liver 
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Interventions Treatment group
• Pre-emptive oral ganciclovir 1000 mg 3 times daily for 8 weeks
Control group
• Placebo
Outcomes 1. CMV disease
2. Acute rejection
3. Other infections
Notes • Method for detection of CMV infection: qualitative PCR for CMV DNA
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomisation occurred via predetermined randomisation chart
Allocation concealment
(selection bias)
Low risk Allocation performed by unblinded pharmacist
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Participants and study personnel were blinded and oral placebo treatment
was visually identical to oral ganciclovir
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not reported and unclear whether outcome assessors were blinded to treat-
ment groups.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk No missing data
Selective reporting (re-
porting bias)
High risk Outcomes of interest not reported: Death and gra@ loss
Other bias High risk Roche pharmaceuticals supplied oral ganciclovir
Paya 2002 Liver  (Continued)
 
 
Methods • Study design: parallel RCT• Follow-up period: 6 months
Participants • Country: Brazil• Setting: NS• CMV status: D/R+, D+/R-, D-/R-• Kidney transplant recipients• Number: 34• Mean age: NS
Interventions Treatment group
Queiroga 2003 Kidney 
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• Pre-emptive oral ganciclovir (dose/route not specified)
Control group
• Ganciclovir 750 g 3 times/d for 90 days
Outcomes 1. CMV disease
2. CMV infection
3. All-cause mortality
4. Gra@ loss
Notes • Method for detection of CMV infection: pp65 antigenaemia > 3 positive cell/30 x 104
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomisation reported but method not specified
Allocation concealment
(selection bias)
Unclear risk Authors did not report method used to conceal allocation of patients
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Not blinded as placebo was not given to pre-emptive group. The interpretation
of clinical symptoms could be influenced by blinding
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Outcome analysis was likely performed by the study investigators
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk No missing data
Selective reporting (re-
porting bias)
High risk All outcomes specified in methods were reported; however, acute rejection
was not reported
Other bias Unclear risk No sponsorship of trial was stated
Queiroga 2003 Kidney  (Continued)
 
 
Methods • Study design: parallel RCT• Follow-up period: 4 months
Participants • Country: Germany• Setting: University• CMV status: D/R+, D+/R-, D-/R-• Liver transplant recipients• Number: 60• Mean age ± SE: treatment group (53 ± 2 years); control group (49 ± 2 years)
Interventions Treatment group
Rayes 2001 Liver 
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• Pre-emptive oral ganciclovir 1000 mg x 3 times/d for 14 days
Control group
• No treatment (treatment given when CMV disease presented)
Outcomes 1. CMV disease and syndrome
2. CMV infection
3. Acute rejection
4. Adverse events
5. All-cause mortality
Notes • Method for detection of CMV infection: pp65 antigenaemia > 1 positive cell/1 x 104; qualitative PCR
for CMV DNA
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomisation reported but method not specified
Allocation concealment
(selection bias)
Unclear risk Authors did not report method used to conceal allocation of patients
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Different treatment schemes oral versus intravenous therefore not blinded.
The interpretation of clinical symptoms could be influenced by blinding
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Outcome analysis was likely performed by the study investigators
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk No missing data
Selective reporting (re-
porting bias)
Low risk All outcomes specified in methods are reported and all outcomes of impor-
tance were included
Other bias Unclear risk No sponsorship of trial was stated
Rayes 2001 Liver  (Continued)
 
 
Methods • Study design: parallel RCT• Primary follow-up period: 12 months. 4 year follow-up data
Participants • Country: Czech Republic• Setting: University• CMV status: D/R+, D+/R-, D-/R-• Kidney transplant recipients• Number: 70• Mean age ± SD: treatment (50 ± 13 years); control group: 48 ± 12 years)
Reischig 2008 Kidney 
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Interventions Treatment group
• Pre-emptive oral valganciclovir 900 mg twice/d for at least 14 days or until test negative
Control group
• Prophylactic oral valaciclovir 2 g 4 times/d for 3 months starting 1 to 7 days post transplantation
Outcomes 1. CMV disease
2. CMV infection
3. All-cause mortality
4. Gra@ loss5. Other infections
5. Acute rejection
6. Time to development of CMV
7. Adverse events
Notes • Method for detection of CMV infection: quantitative PCR on whole blood for CMV DNAemia with a cut
oB value of > 2000 copies/mL
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomisation occurred 1:1 to either group via a random number table
Allocation concealment
(selection bias)
Unclear risk Authors did not report method used to conceal allocation of patients
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open labelled. The interpretation of clinical symptoms could be influenced by
blinding
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Outcome analysis was likely performed by the study investigators
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk No missing data
Selective reporting (re-
porting bias)
Low risk All outcomes specified in methods are reported and all outcomes of impor-
tance were included
Other bias Low risk Study was supported by an award from the Ministry of Education, Youth and
Physical Training of the Czech Republic
Reischig 2008 Kidney  (Continued)
 
 
Methods • Study design: parallel RCT• Follow-up period: 12 months
Participants • Country: Norway• Setting: University
Sagedal 2003 Kidney 
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• CMV status: D/R+, D+/R-• Kidney transplant recipients (1st transplant only)• Number: 80• Mean age; range: treatment group (55 years; 22 to 79); control group (56 years; 21 to 78)
Interventions Treatment group
• Pre-emptive oral ganciclovir 100 mg x 3 times/d (duration not specified)
Control group
• No treatment
Outcomes 1. CMV syndrome and disease
2. Acute rejection
3. All-cause mortality
4. Serum creatinine
Notes • Method for detection of CMV infection: pp65 antigenaemia > 1 positive cell/10 x 104
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomisation reported but method not specified
Allocation concealment
(selection bias)
Unclear risk Authors did not report method used to conceal allocation of patients
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open-labelled. The interpretation of clinical symptoms could be influenced by
blinding
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Outcome analysis was likely performed by the study investigators
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Infection other than CMV were not reported past 12 weeks, however, this
would not affect the study outcomes
Selective reporting (re-
porting bias)
Low risk All outcomes specified in methods are reported and all outcomes of impor-
tance were included
Other bias High risk Trial was supported by grants from the Research Council of Norway and Hof-
mann-La Roche, Norway
Gancicolvir was supplied by F. Hoffmann La-Roche AG
Sagedal 2003 Kidney  (Continued)
 
 
Methods • Study design: parallel RCT• Follow-up period: 6 months
Singh 1994 Liver 
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Participants • Country: USA• Setting: University• CMV status: D/R+, D+/R-, D-/R-• Liver transplant recipients: 1st transplant (44); 2nd transplant (3)• Number: 47• Mean age; range: treatment group (49 years; 22 to 66); control group (45 years; 21 to 69)
Interventions Treatment group
• Pre-emptive IV ganciclovir 5 mg/kg twice/d x 7 days
Control group
• Oral acyclovir 800 mg x 4 times/d x 24 weeks
Outcomes 1. CMV syndrome and disease
2. All-cause mortality
3. Gra@ loss
4. Adverse events
Notes • Method for detection of CMV infection: shell vial culture; EIA (titre > 0.79 positive)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomisation was stratified by CMV serostatus of donor and recipient. Ran-
domisation process by blocks of 4
Allocation concealment
(selection bias)
Unclear risk Authors did not report method used to conceal allocation of patients
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Not reported, however, different medications and administration routes were
used therefore it was considered not to be blinded. The interpretation of clini-
cal symptoms could be influenced by blinding
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Outcome analysis was likely performed by the study investigators
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk No missing data
Selective reporting (re-
porting bias)
High risk All outcomes specified in methods were reported; however, acute rejection
was not reported
Other bias Unclear risk No sponsorship of trial was stated
Singh 1994 Liver  (Continued)
 
 
Methods • Study design: parallel RCT• Follow-up period: 3 months
Singh 2000 Liver 
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Participants • Country: USA• Setting: University• CMV status: D/R+, D+/R-, D-/R-• Liver transplant recipients• Number: 22• Mean age: Treatment group (50.9 years); control group (49.9 years)
Interventions Treatment group
• Pre-emptive oral ganciclovir 2000 mg 3 times/d for 2 weeks, then 1000 mg 3 times/d for 4 weeks
Control group
• Pre-emptive ganciclovir IV 5 mg/kg every 12 hours for 7 days
Outcomes 1. CMV disease and syndrome
2. All-cause mortality
3. Other infections
4. Adverse events
5. Cost analysis
Notes • Method for detection of CMV infection: pp65 antigenaemia > 1 positive cell/20 x 104
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomisation reported but method not specified
Allocation concealment
(selection bias)
Unclear risk Authors did not report method used to conceal allocation of patients
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Not reported. However, different administration routes were used and consid-
ered not to be blinded. The interpretation of clinical symptoms could be influ-
enced by blinding
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Outcome analysis was likely performed by the study investigators
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk No missing data
Selective reporting (re-
porting bias)
High risk All outcomes specified in methods were reported; however, gra@ loss and
acute rejection were not reported
Other bias Unclear risk No sponsorship of study was stated
Singh 2000 Liver  (Continued)
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• Follow-up period: 12 months
Participants • Country: Germany/Austria• Setting: Multicentre• CMV status: D+/R+, D-/R+• Kidney transplant recipients• Number: 296• Mean age ± SD: treatment group (54.2 ± 12.0 years); control group (51.1 ± 13.6 years)
Interventions Treatment group
• Pre-emptive oral valganciclovir 900 mg twice/d for at least 14 days or until test negative (< 400 copies/
mL) with prophylaxis period consisting of 450 mg valganciclovir twice/d for 28 days
Control group
• Prophylactic oral valganciclovir 900 mg twice/d for 100 days initiated within 14 days post transplan-
tation
Outcomes 1. CMV disease and syndrome
2. CMV infection
3. Other infections
4. Adverse events
5. All-cause mortality
6. Acute rejection
7. Gra@ loss
Notes • Method for CMV detection was RT-PCR with cut oB value > 400 copies/mL
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method of randomisation not specified
Allocation concealment
(selection bias)
Low risk 1:1 central allocation via phone
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open-labelled. The interpretation of clinical symptoms could be influenced by
blinding
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Outcome analysis was likely performed by the study investigators.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk No missing data
Selective reporting (re-
porting bias)
Low risk All outcomes specified in methods are reported and all outcomes of impor-
tance were included
Other bias High risk Valgancicolvir was supplied by Roche Pharma AG, Germany
Witzke 2012 Kidney  (Continued)
Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
44
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
 
 
Methods • Study design: parallel RCT• Follow-up period: 6 months
Participants • Country: South Korea• Setting: University• CMV status: D/R+• Kidney transplant recipients• Number: 31• Mean age: NS
Interventions Treatment group
• Pre-emptive IV ganciclovir 5 mg/kg twice/d for 2 weeks
Control group
• No treatment
Outcomes 1. CMV syndrome and disease
2. CMV infection
Notes • Method for detection of CMV infection: pp65 antigenaemia > 1 positive cell/5 x 104; CMV IgM index >
0.500
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomisation reported but method not specified
Allocation concealment
(selection bias)
Unclear risk Authors did not report method used to conceal allocation of patients
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Not reported. However, no placebo was given to the untreated control group.
This would enable investigators to identify participant's groups. The interpre-
tation of clinical symptoms could be influenced by blinding
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Outcome analysis was likely performed by the study investigators
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk No missing data
Selective reporting (re-
porting bias)
High risk All outcomes specified in methods were reported; however, death, gra@ loss
and acute rejection outcomes were not reported
Other bias Low risk Study was supported by a research grant from the Clinical Research fund (BKB)
of the Catholic Medical Centre
Yang 1998 Kidney 
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CMV - cytomegalovirus; DNA - deoxyribonucleic acid; D/R+ donor unknown/recipient CMV positive; D+/R- donor CMV positive/recipient CMV
negative; D-/R- donor CMV negative/recipient CMV negative; IV - intravenous; NaCl - sodium chloride; NS - not stated; PCR - polymerase
chain reaction; SD - standard deviation; SE - standard error
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Ahsan 1997 Kidney Prophylaxis RCT
Ahsan 1998 Not RCT (sequential)
Arbo 2000 Economic evaluation of previous study
Badley 1997 Liver Prophylaxis RCT
Balfour 1989 Kidney Prophylaxis RCT
Barkholt 1999 Liver Prophylaxis RCT
Brennan 1997b Kidney Not a pre-emptive study and primary outcome was herpes virus (HHV-7) infection
Cohen 1993 Liver Prophylaxis RCT
Conti 1995 Kidney Prophylaxis RCT
Denny 2002 Not an RCT
Devolder 2010 Ineligible intervention
Dickinson 1996 IgG to prevent CMV
Duncan 1993 Lung Prophylaxis RCT
Egan 2002 Heart Prophylaxis RCT
Euro-SPK 2005 RCT comparing tacrolimus and cyclosporin
Falagas 1997 Included both non-randomised patients and patients from a previous study
Fehir 1989 Non-randomised patients included
Ferreira 2004 CMV data from several studies comparing immunosuppressive regimens
Fishman 2000 Retrospective study
Flechner 1998 Kidney Prophylaxis RCT
Gane 1997 Liver Prophylaxis RCT
Gavalda 1997 Liver Prophylaxis RCT
Gerna 2003 Qualitative molecular assay for detection of a late (pp67) HCMV mRNA versus quantita-
tive antigenaemia
Gerna 2007 Evaluation of cytomegalovirus DNAemia versus pp65-antigenaemia
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Study Reason for exclusion
Green 1997 Liver Prophylaxis RCT
Greger 1988 Comparison of immunosuppression regimes
Griffiths 2010 Ineligable intervention (haematopoetic stem cell transplant recipients)
Hecht 1988 Case reports of patients treated with ganciclovir
Hertz 1998 Heart/Lung Prophylaxis RCT
Hibberd 1995 Kidney Prophylaxis RCT
IMPACT Study 2010 TX Prophylaxis RCT
Jurim 1996 Subgroup of previous study; outcome hepatitis B
Kim 2000 Economic evaluation of previous study
King 1999 IgG versus antiviral to prevent CMV
Kletzmayr 1996 Kidney Prophylaxis RCT
Kletzmayr 2000 Not RCT; historical controls
Leray 1995 Kidney Prophylaxis RCT
Lowance 1999 Kidney Prophylaxis RCT
Lumbreras 1993 Not RCT; historical controls
MacDonald 1991 Ineligible intervention
Macdonald 1995 Heart Prophylaxis RCT
Marker 1980 Intervention study. Included both randomised and non-randomised participants
Mattes 2004 Included non-solid organ transplants in analysis
Merigan 1992 Heart Prophylaxis RCT
Moreno 1999 Not RCT
Mullen 1998 Retrospective study
Murray 1997 Economic evaluation of CMV treatments
Nakazato 1993 Liver Prophylaxis RCT
Palmer 2010 Prophylaxis RCT
Paya 2004 All Prophylaxis RCT
Pescovitz 2009 Prophylaxis RCT
Pouteil 1991 HLA compatibility with CMV infection
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Study Reason for exclusion
Pouteil-Noble 1996 Kidney Prophylaxis RCT
Qiu 2008 Kidney Not an RCT
Reischig 2005 Kidney Prophylaxis RCT
Rondeau 1993 Kidney Prophylaxis RCT
Rostaing 1994 Kidney Prophylaxis RCT
Rubin 2002 All Prophylaxis RCT
Saliba 1993 Liver Prophylaxis RCT
Schnitzler 2000 Re-analysis of previous study (1992)
Singh 1995 Not RCT
Singh 2002 Prophylaxis RCT
Speich 1999 Not RCT; sequential enrolment
Tian 2005 Kidney Not RCT
Tong 2002 Primary outcome was herpes virus (HHV-7) infection
Turgeon 1998 Not RCT; sequential enrolment
Valantine 1999 Post hoc analysis
VICTOR Study 2007 Treatment study. Assessed genetic polymorphism impact on CMV infection and other
herpes virus co-infections
Villano 2010 Prophylaxis RCT
Winston 1995 Liver Prophylaxis RCT
Winston 2003 Liver Prophylaxis RCT
Winston 2004 Liver Prophylaxis RCT
Yang 1999 Unable to determine if participants were randomised
CMV - cytomegalovirus; RCT - randomised control trial
 
Characteristics of studies awaiting assessment [ordered by study ID]
 
Methods Open label RCT, sequentially numbered envelopes.
Participants 1. Male or female > 16 years of age 
2. Patients undergoing liver transplantation 
3. Single or multi-organ transplant 
4. Patients meet transplant criteria 
Scott 2011 Liver 
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5. Chronic liver disease or fulminant hepatic failure 
6. Able to give written informed consent
Interventions High risk group and prophylaxis group are assigned to receive 900mg (two 450mg tablets) of val-
ganciclovir (Valcyte) once daily for 3 months commenced within 72 hrs after liver transplantation
and monitored regularly for CMV infection/disease. Dose will be changed based on creatinine clear-
ance.
Pre- Emptive group Monitored regularly for CMV infection only. If this occurs patients will be given
5 mg/kg intravenously over one hour, of ganciclovir (GCV) twice daily for 2 weeks CMV infection is
determined on testing with Qualitative Polymerease chain reaction (PCR) 
Valganciclovir doses as per creatinine clearance: 
Creatinine clearance >/=60 ml/min900mg daily 
Creatinine clearance 40-59 ml/min 450mg daily 
Creatinine clearance 25-39 ml/min450mg second daily 
Creatinine clearance 10-24 ml/min450 mg twice weekly
Outcomes Primary incidence of CMV infection and disease
Assess viral characteristics of infection
Antiviral resistant CMV
Incidence of opportunistic viral infections
Drug efficacy
Notes Unfunded
Scott 2011 Liver  (Continued)
 
Characteristics of ongoing studies [ordered by study ID]
 
Trial name or title A randomized trial comparing valcyte CMV prophylaxis versus pre-emptive therapy after renal
transplantation using proteomics for monitoring of gra@ alteration
Methods Open label RCT
Participants Unknown
Interventions Valganciclovir CMV prophylaxis for 100 days versus valganciclovir pre-emptive therapy
Outcomes CMV infection
CMV disease
Gra@ loss
Starting date May 2006
Contact information  
Notes  
NCT00372229 
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Trial name or title Prevention of transplant atherosclerosis with everolimus and anti-cytomegalovirus therapy
Methods Open label RCT
Participants Estimated 100
Interventions Pre-emptive strategy with valganciclovir plus everolimus
Prophylaxis with valganciclovir plus mycophenolate
Prophylaxis with valganciclovir plus everolimus
Pre-emptive mycophenolate
Outcomes CMV infection
Starting date April 2009
Contact information Luciano Potena, MD PhD
Francesco Grigioni, MD PhD
Notes  
NCT00966836 
 
 
Trial name or title Prophylaxis versus preemptive therapy for the prevention of CMV in high-risk R-D+ liver transplant
recipients
Methods Single blind (outcome assessors), RCT
Participants Estimated 180
Interventions Prophylaxis with valganciclovir for 100 days post transplantation versus subjects monitored with
CMV PCR testing and given valganciclovir therapy only if PCR is positive. Therapy is stopped after
second negative PCR test
Outcomes CMV disease
All-cause mortality
Starting date July 2012
Contact information Principal Investigator: Nina Singh, MD
Notes  
NCT01552369 
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Comparison 1.   Pre-emptive medication for CMV viraemia versus placebo or standard care
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 All symptomatic CMV disease 6 288 Risk Ratio (M-H, Random, 95% CI) 0.29 [0.11, 0.80]
2 CMV organ involvement 5 217 Risk Ratio (M-H, Random, 95% CI) 0.41 [0.06, 2.63]
3 CMV associated symptoms 5 217 Risk Ratio (M-H, Random, 95% CI) 0.28 [0.06, 1.21]
4 Acute rejection 3 185 Risk Ratio (M-H, Random, 95% CI) 1.21 [0.69, 2.12]
5 All-cause mortality and gra@ loss 3   Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 All-cause mortality 3 176 Risk Ratio (M-H, Random, 95% CI) 1.23 [0.35, 4.30]
5.2 Gra@ loss 1 36 Risk Ratio (M-H, Random, 95% CI) 0.28 [0.01, 5.35]
6 Other infections 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
7 Adverse effects 2   Risk Ratio (M-H, Random, 95% CI) Subtotals only
7.1 Leucopenia 2 114 Risk Ratio (M-H, Random, 95% CI) 1.54 [0.16, 15.36]
7.2 Kidney dysfunction 1 36 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.18, 4.92]
 
 
Analysis 1.1.   Comparison 1 Pre-emptive medication for CMV viraemia
versus placebo or standard care, Outcome 1 All symptomatic CMV disease.
Study or subgroup Pre-emptive place-
bo/std care
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Paya 2002 Liver 0/35 5/34 9.13% 0.09[0.01,1.54]
Yang 1998 Kidney 0/15 7/16 9.5% 0.07[0,1.14]
Koetz 2001 Kidney 0/5 5/7 9.94% 0.12[0.01,1.79]
Sagedal 2003 Kidney 2/42 11/38 20.37% 0.16[0.04,0.7]
Rayes 2001 Liver 3/30 6/30 22.23% 0.5[0.14,1.82]
Brennan 1997a Kidney 6/15 9/21 28.83% 0.93[0.42,2.06]
   
Total (95% CI) 142 146 100% 0.29[0.11,0.8]
Total events: 11 (Pre-emptive), 43 (placebo/std care)  
Heterogeneity: Tau2=0.75; Chi2=10.8, df=5(P=0.06); I2=53.7%  
Test for overall effect: Z=2.39(P=0.02)  
Pre-emptive 5000.002 100.1 1 Placebo/std care
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Analysis 1.2.   Comparison 1 Pre-emptive medication for CMV viraemia
versus placebo or standard care, Outcome 2 CMV organ involvement.
Study or subgroup Pre-emptive Place-
bo/std care
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Brennan 1997a Kidney 0/15 1/21 21.47% 0.46[0.02,10.54]
Koetz 2001 Kidney 0/5 0/7   Not estimable
Rayes 2001 Liver 3/30 1/30 31.16% 3[0.33,27.23]
Sagedal 2003 Kidney 0/40 8/38 24.35% 0.06[0,0.94]
Yang 1998 Kidney 0/15 2/16 23.02% 0.21[0.01,4.1]
   
Total (95% CI) 105 112 100% 0.41[0.06,2.63]
Total events: 3 (Pre-emptive), 12 (Placebo/std care)  
Heterogeneity: Tau2=1.59; Chi2=5.44, df=3(P=0.14); I2=44.86%  
Test for overall effect: Z=0.94(P=0.35)  
Pre-emptive 5000.002 100.1 1 Placebo/std care
 
 
Analysis 1.3.   Comparison 1 Pre-emptive medication for CMV viraemia
versus placebo or standard care, Outcome 3 CMV associated symptoms.
Study or subgroup Pre-emptive Place-
bo/std care
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Brennan 1997a Kidney 6/15 8/21 36.15% 1.05[0.46,2.4]
Koetz 2001 Kidney 0/5 5/7 17.24% 0.12[0.01,1.79]
Rayes 2001 Liver 0/30 5/30 16.12% 0.09[0.01,1.57]
Sagedal 2003 Kidney 0/40 1/38 14.11% 0.32[0.01,7.55]
Yang 1998 Kidney 0/15 5/16 16.38% 0.1[0.01,1.61]
   
Total (95% CI) 105 112 100% 0.28[0.06,1.21]
Total events: 6 (Pre-emptive), 24 (Placebo/std care)  
Heterogeneity: Tau2=1.38; Chi2=8.36, df=4(P=0.08); I2=52.18%  
Test for overall effect: Z=1.7(P=0.09)  
Pre-emptive 2000.005 100.1 1 Placebo/std care
 
 
Analysis 1.4.   Comparison 1 Pre-emptive medication for CMV
viraemia versus placebo or standard care, Outcome 4 Acute rejection.
Study or subgroup Pre-emptive Place-
bo/std care
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Brennan 1997a Kidney 3/15 4/21 17.48% 1.05[0.27,4.02]
Paya 2002 Liver 0/35 1/34 3.14% 0.32[0.01,7.69]
Sagedal 2003 Kidney 16/42 11/38 79.38% 1.32[0.7,2.47]
   
Total (95% CI) 92 93 100% 1.21[0.69,2.12]
Total events: 19 (Pre-emptive), 16 (Placebo/std care)  
Heterogeneity: Tau2=0; Chi2=0.79, df=2(P=0.67); I2=0%  
Test for overall effect: Z=0.67(P=0.5)  
Pre-emptive 1000.01 100.1 1 Placebo
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Analysis 1.5.   Comparison 1 Pre-emptive medication for CMV viraemia versus
placebo or standard care, Outcome 5 All-cause mortality and graC loss.
Study or subgroup Pre-emptive Place-
bo/std care
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.5.1 All-cause mortality  
Brennan 1997a Kidney 0/15 0/21   Not estimable
Rayes 2001 Liver 4/30 3/30 79.05% 1.33[0.33,5.45]
Sagedal 2003 Kidney 1/42 1/38 20.95% 0.9[0.06,13.97]
Subtotal (95% CI) 87 89 100% 1.23[0.35,4.3]
Total events: 5 (Pre-emptive), 4 (Placebo/std care)  
Heterogeneity: Tau2=0; Chi2=0.06, df=1(P=0.8); I2=0%  
Test for overall effect: Z=0.32(P=0.75)  
   
1.5.2 GraC loss  
Brennan 1997a Kidney 0/15 2/21 100% 0.28[0.01,5.35]
Subtotal (95% CI) 15 21 100% 0.28[0.01,5.35]
Total events: 0 (Pre-emptive), 2 (Placebo/std care)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.85(P=0.39)  
Pre-emptive 1000.01 100.1 1 Placebo/std care
 
 
Analysis 1.6.   Comparison 1 Pre-emptive medication for CMV viraemia
versus placebo or standard care, Outcome 6 Other infections.
Study or subgroup Pre-emptive placebo/std care Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Paya 2002 Liver 1/35 2/34 0.49[0.05,5.11]
Pre-emptive 500.02 100.1 1 Placebo/std care
 
 
Analysis 1.7.   Comparison 1 Pre-emptive medication for CMV
viraemia versus placebo or standard care, Outcome 7 Adverse eKects.
Study or subgroup Pre-emptive Place-
bo/std care
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.7.1 Leucopenia  
Brennan 1997a Kidney 0/15 1/21 48.1% 0.46[0.02,10.54]
Sagedal 2003 Kidney 2/40 0/38 51.9% 4.76[0.24,95.96]
Subtotal (95% CI) 55 59 100% 1.54[0.16,15.36]
Total events: 2 (Pre-emptive), 1 (Placebo/std care)  
Heterogeneity: Tau2=0.3; Chi2=1.12, df=1(P=0.29); I2=10.86%  
Test for overall effect: Z=0.37(P=0.71)  
   
1.7.2 Kidney dysfunction  
Brennan 1997a Kidney 2/15 3/21 100% 0.93[0.18,4.92]
Subtotal (95% CI) 15 21 100% 0.93[0.18,4.92]
Pre-emptive 1000.01 100.1 1 Placebo/std care
Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
53
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Study or subgroup Pre-emptive Place-
bo/std care
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total events: 2 (Pre-emptive), 3 (Placebo/std care)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.08(P=0.94)  
Pre-emptive 1000.01 100.1 1 Placebo/std care
 
 
Comparison 2.   Pre-emptive medication versus prophylaxis
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 All symptomatic CMV disease 7 753 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.43, 2.44]
2 CMV infection 7 727 Risk Ratio (M-H, Random, 95% CI) 2.06 [1.44, 2.96]
3 All-cause mortality and gra@
loss
7   Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 All-cause mortality 7 753 Risk Ratio (M-H, Random, 95% CI) 1.19 [0.56, 2.51]
3.2 Gra@ loss 7 753 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.41, 2.82]
4 Acute rejection 6 693 Risk Ratio (M-H, Random, 95% CI) 1.23 [0.75, 2.03]
5 Other infections 2   Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 Bacterial 2 168 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.55, 1.43]
5.2 Viral 1 70 Risk Ratio (M-H, Random, 95% CI) 1.57 [0.92, 2.70]
5.3 Fungal 1 70 Risk Ratio (M-H, Random, 95% CI) 1.89 [0.18, 19.89]
6 Adverse effects 6   Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 Leucopenia 6 729 Risk Ratio (M-H, Random, 95% CI) 0.42 [0.20, 0.90]
6.2 Neurological dysfunction 3 187 Risk Ratio (M-H, Random, 95% CI) 0.58 [0.17, 1.96]
6.3 Kidney dysfunction 1 47 Risk Ratio (M-H, Random, 95% CI) 0.35 [0.01, 8.11]
6.4 Anaemia 2 218 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.48, 1.73]
6.5 Thrombocytopenia 2 218 Risk Ratio (M-H, Random, 95% CI) 1.16 [0.54, 2.48]
6.6 Malignancy 1 70 Risk Ratio (M-H, Random, 95% CI) 0.32 [0.01, 7.48]
6.7 Hypertension 1 70 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.91, 1.27]
6.8 Hypercholesterolaemia 1 70 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.58, 1.10]
6.9 Cardiac events 1 70 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.24, 1.92]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
6.10 Neutropenia 3 514 Risk Ratio (M-H, Random, 95% CI) 0.51 [0.27, 0.95]
7 D+/R- serostatus 2   Risk Ratio (M-H, Random, 95% CI) Subtotals only
7.1 Symptomatic CMV 2 39 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.12, 8.02]
7.2 CMV infection 2 39 Risk Ratio (M-H, Random, 95% CI) 1.16 [0.71, 1.92]
8 D+ or D-/R+ serostatus 2   Risk Ratio (M-H, Random, 95% CI) Subtotals only
8.1 Symptomatic CMV 2 129 Risk Ratio (M-H, Random, 95% CI) 0.20 [0.02, 1.74]
8.2 CMV infection 2 129 Risk Ratio (M-H, Random, 95% CI) 2.07 [1.25, 3.42]
 
 
Analysis 2.1.   Comparison 2 Pre-emptive medication versus prophylaxis, Outcome 1 All symptomatic CMV disease.
Study or subgroup Pre-emptive Prophylaxis Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Queiroga 2003 Kidney 0/25 0/9   Not estimable
Khoury 2006 Kidney 1/49 4/49 10.52% 0.25[0.03,2.16]
Singh 1994 Liver 1/23 7/24 11.45% 0.15[0.02,1.12]
Reischig 2008 Kidney 2/36 3/34 13.71% 0.63[0.11,3.54]
Jung 2001 Kidney 3/36 3/34 15.52% 0.94[0.2,4.36]
Kliem 2008 Kidney 12/65 5/73 21.61% 2.7[1,7.24]
Witzke 2012 Kidney 43/150 17/146 27.18% 2.46[1.47,4.11]
   
Total (95% CI) 384 369 100% 1.02[0.43,2.44]
Total events: 62 (Pre-emptive), 39 (Prophylaxis)  
Heterogeneity: Tau2=0.65; Chi2=13.56, df=5(P=0.02); I2=63.12%  
Test for overall effect: Z=0.05(P=0.96)  
Pre-emptive 1000.01 100.1 1 Prophylaxis
 
 
Analysis 2.2.   Comparison 2 Pre-emptive medication versus prophylaxis, Outcome 2 CMV infection.
Study or subgroup Pre-emptive Prophylaxis Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Queiroga 2003 Kidney 19/25 0/9 1.66% 15[1,225.6]
Kliem 2008 Kidney 33/65 13/73 14.84% 2.85[1.65,4.93]
Witzke 2012 Kidney 58/150 16/146 15.64% 3.53[2.13,5.84]
Khoury 2006 Kidney 29/49 14/49 15.72% 2.07[1.26,3.42]
Gerna 2008 Liver 9/11 7/10 15.87% 1.17[0.71,1.91]
Jung 2001 Kidney 27/36 14/34 16.79% 1.82[1.17,2.84]
Reischig 2008 Kidney 33/36 20/34 19.48% 1.56[1.16,2.1]
   
Total (95% CI) 372 355 100% 2.06[1.44,2.96]
Pre-emptive 5000.002 100.1 1 Prophylaxis
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Study or subgroup Pre-emptive Prophylaxis Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total events: 208 (Pre-emptive), 84 (Prophylaxis)  
Heterogeneity: Tau2=0.15; Chi2=20.78, df=6(P=0); I2=71.13%  
Test for overall effect: Z=3.91(P<0.0001)  
Pre-emptive 5000.002 100.1 1 Prophylaxis
 
 
Analysis 2.3.   Comparison 2 Pre-emptive medication versus
prophylaxis, Outcome 3 All-cause mortality and graC loss.
Study or subgroup Pre-emptive Prophylaxis Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.3.1 All-cause mortality  
Khoury 2006 Kidney 0/49 0/49   Not estimable
Reischig 2008 Kidney 0/36 1/34 5.62% 0.32[0.01,7.48]
Queiroga 2003 Kidney 5/25 0/9 7.18% 4.23[0.26,69.69]
Jung 2001 Kidney 4/36 1/34 12.29% 3.78[0.44,32.13]
Witzke 2012 Kidney 2/150 2/146 14.86% 0.97[0.14,6.82]
Singh 1994 Liver 3/23 3/24 25.22% 1.04[0.23,4.65]
Kliem 2008 Kidney 4/65 5/73 34.84% 0.9[0.25,3.2]
Subtotal (95% CI) 384 369 100% 1.19[0.56,2.51]
Total events: 18 (Pre-emptive), 12 (Prophylaxis)  
Heterogeneity: Tau2=0; Chi2=2.89, df=5(P=0.72); I2=0%  
Test for overall effect: Z=0.45(P=0.65)  
   
2.3.2 GraC loss  
Khoury 2006 Kidney 1/49 0/49 7.46% 3[0.13,71.89]
Jung 2001 Kidney 0/36 4/34 8.68% 0.11[0.01,1.88]
Singh 1994 Liver 4/23 0/24 8.77% 9.38[0.53,164.94]
Reischig 2008 Kidney 1/36 3/34 12.7% 0.31[0.03,2.88]
Queiroga 2003 Kidney 3/25 1/9 13.36% 1.08[0.13,9.1]
Witzke 2012 Kidney 4/150 7/146 23.79% 0.56[0.17,1.86]
Kliem 2008 Kidney 10/65 4/73 25.23% 2.81[0.93,8.52]
Subtotal (95% CI) 384 369 100% 1.07[0.41,2.82]
Total events: 23 (Pre-emptive), 19 (Prophylaxis)  
Heterogeneity: Tau2=0.65; Chi2=10.25, df=6(P=0.11); I2=41.45%  
Test for overall effect: Z=0.14(P=0.89)  
Pre-emptive 2000.005 100.1 1 Prophylaxis
 
 
Analysis 2.4.   Comparison 2 Pre-emptive medication versus prophylaxis, Outcome 4 Acute rejection.
Study or subgroup Pre-emptive Prophylaxis Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Gerna 2008 Liver 2/11 1/10 4.39% 1.82[0.19,17.12]
Jung 2001 Kidney 4/49 1/49 4.71% 4[0.46,34.52]
Reischig 2008 Kidney 13/36 5/34 17.25% 2.46[0.98,6.15]
Khoury 2006 Kidney 9/36 9/34 20.23% 0.94[0.43,2.09]
Kliem 2008 Kidney 18/65 14/73 25.66% 1.44[0.78,2.67]
Witzke 2012 Kidney 18/150 27/146 27.75% 0.65[0.37,1.13]
Pre-emptive 1000.01 100.1 1 Prophylaxis
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Study or subgroup Pre-emptive Prophylaxis Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
   
Total (95% CI) 347 346 100% 1.23[0.75,2.03]
Total events: 64 (Pre-emptive), 57 (Prophylaxis)  
Heterogeneity: Tau2=0.15; Chi2=8.93, df=5(P=0.11); I2=44.01%  
Test for overall effect: Z=0.83(P=0.41)  
Pre-emptive 1000.01 100.1 1 Prophylaxis
 
 
Analysis 2.5.   Comparison 2 Pre-emptive medication versus prophylaxis, Outcome 5 Other infections.
Study or subgroup Pre-emptive Prophylaxis Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.5.1 Bacterial  
Khoury 2006 Kidney 5/49 9/49 19.94% 0.56[0.2,1.54]
Reischig 2008 Kidney 20/36 19/34 80.06% 0.99[0.65,1.51]
Subtotal (95% CI) 85 83 100% 0.89[0.55,1.43]
Total events: 25 (Pre-emptive), 28 (Prophylaxis)  
Heterogeneity: Tau2=0.03; Chi2=1.18, df=1(P=0.28); I2=15.58%  
Test for overall effect: Z=0.5(P=0.62)  
   
2.5.2 Viral  
Reischig 2008 Kidney 20/36 12/34 100% 1.57[0.92,2.7]
Subtotal (95% CI) 36 34 100% 1.57[0.92,2.7]
Total events: 20 (Pre-emptive), 12 (Prophylaxis)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.64(P=0.1)  
   
2.5.3 Fungal  
Reischig 2008 Kidney 2/36 1/34 100% 1.89[0.18,19.89]
Subtotal (95% CI) 36 34 100% 1.89[0.18,19.89]
Total events: 2 (Pre-emptive), 1 (Prophylaxis)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.53(P=0.6)  
Pre-emptive 1000.01 100.1 1 Prophylaxis
 
 
Analysis 2.6.   Comparison 2 Pre-emptive medication versus prophylaxis, Outcome 6 Adverse eKects.
Study or subgroup Pre-emptive Prophylaxis Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.6.1 Leucopenia  
Singh 1994 Liver 0/23 1/24 5.05% 0.35[0.01,8.11]
Jung 2001 Kidney 0/36 9/34 6.19% 0.05[0,0.82]
Khoury 2006 Kidney 1/49 2/49 8.24% 0.5[0.05,5.34]
Kliem 2008 Kidney 1/74 11/74 10.59% 0.09[0.01,0.69]
Reischig 2008 Kidney 6/36 11/34 28.16% 0.52[0.21,1.24]
Witzke 2012 Kidney 40/150 52/146 41.77% 0.75[0.53,1.06]
Subtotal (95% CI) 368 361 100% 0.42[0.2,0.9]
Total events: 48 (Pre-emptive), 86 (Prophylaxis)  
Pre-emptive 5000.002 100.1 1 Prophylaxis
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Study or subgroup Pre-emptive Prophylaxis Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Heterogeneity: Tau2=0.32; Chi2=9.14, df=5(P=0.1); I2=45.28%  
Test for overall effect: Z=2.24(P=0.03)  
   
2.6.2 Neurological dysfunction  
Jung 2001 Kidney 0/36 2/34 13.95% 0.19[0.01,3.8]
Singh 1994 Liver 0/23 3/24 14.69% 0.15[0.01,2.73]
Reischig 2008 Kidney 14/36 14/34 71.36% 0.94[0.53,1.68]
Subtotal (95% CI) 95 92 100% 0.58[0.17,1.96]
Total events: 14 (Pre-emptive), 19 (Prophylaxis)  
Heterogeneity: Tau2=0.46; Chi2=2.77, df=2(P=0.25); I2=27.87%  
Test for overall effect: Z=0.88(P=0.38)  
   
2.6.3 Kidney dysfunction  
Singh 1994 Liver 0/23 1/24 100% 0.35[0.01,8.11]
Subtotal (95% CI) 23 24 100% 0.35[0.01,8.11]
Total events: 0 (Pre-emptive), 1 (Prophylaxis)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.66(P=0.51)  
   
2.6.4 Anaemia  
Kliem 2008 Kidney 7/74 8/74 44.46% 0.88[0.33,2.29]
Reischig 2008 Kidney 8/36 8/34 55.54% 0.94[0.4,2.23]
Subtotal (95% CI) 110 108 100% 0.91[0.48,1.73]
Total events: 15 (Pre-emptive), 16 (Prophylaxis)  
Heterogeneity: Tau2=0; Chi2=0.01, df=1(P=0.91); I2=0%  
Test for overall effect: Z=0.28(P=0.78)  
   
2.6.5 Thrombocytopenia  
Kliem 2008 Kidney 3/74 3/74 23.53% 1[0.21,4.79]
Reischig 2008 Kidney 9/36 7/34 76.47% 1.21[0.51,2.9]
Subtotal (95% CI) 110 108 100% 1.16[0.54,2.48]
Total events: 12 (Pre-emptive), 10 (Prophylaxis)  
Heterogeneity: Tau2=0; Chi2=0.05, df=1(P=0.83); I2=0%  
Test for overall effect: Z=0.38(P=0.7)  
   
2.6.6 Malignancy  
Reischig 2008 Kidney 0/36 1/34 100% 0.32[0.01,7.48]
Subtotal (95% CI) 36 34 100% 0.32[0.01,7.48]
Total events: 0 (Pre-emptive), 1 (Prophylaxis)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.71(P=0.48)  
   
2.6.7 Hypertension  
Reischig 2008 Kidney 33/36 29/34 100% 1.07[0.91,1.27]
Subtotal (95% CI) 36 34 100% 1.07[0.91,1.27]
Total events: 33 (Pre-emptive), 29 (Prophylaxis)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.83(P=0.41)  
   
2.6.8 Hypercholesterolaemia  
Reischig 2008 Kidney 22/36 26/34 100% 0.8[0.58,1.1]
Subtotal (95% CI) 36 34 100% 0.8[0.58,1.1]
Pre-emptive 5000.002 100.1 1 Prophylaxis
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Study or subgroup Pre-emptive Prophylaxis Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total events: 22 (Pre-emptive), 26 (Prophylaxis)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.37(P=0.17)  
   
2.6.9 Cardiac events  
Reischig 2008 Kidney 5/36 7/34 100% 0.67[0.24,1.92]
Subtotal (95% CI) 36 34 100% 0.67[0.24,1.92]
Total events: 5 (Pre-emptive), 7 (Prophylaxis)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.74(P=0.46)  
   
2.6.10 Neutropenia  
Kliem 2008 Kidney 0/74 1/74 3.8% 0.33[0.01,8.05]
Reischig 2008 Kidney 5/36 10/34 41.33% 0.47[0.18,1.24]
Witzke 2012 Kidney 8/150 14/146 54.87% 0.56[0.24,1.29]
Subtotal (95% CI) 260 254 100% 0.51[0.27,0.95]
Total events: 13 (Pre-emptive), 25 (Prophylaxis)  
Heterogeneity: Tau2=0; Chi2=0.13, df=2(P=0.94); I2=0%  
Test for overall effect: Z=2.13(P=0.03)  
Test for subgroup differences: Chi2=13.52, df=1 (P=0.14), I2=33.44%  
Pre-emptive 5000.002 100.1 1 Prophylaxis
 
 
Analysis 2.7.   Comparison 2 Pre-emptive medication versus prophylaxis, Outcome 7 D+/R- serostatus.
Study or subgroup Pre-emptive Prophylaxis Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.7.1 Symptomatic CMV  
Reischig 2008 Kidney 2/6 0/4 40.82% 3.57[0.21,59.39]
Khoury 2006 Kidney 1/13 3/16 59.18% 0.41[0.05,3.49]
Subtotal (95% CI) 19 20 100% 0.99[0.12,8.02]
Total events: 3 (Pre-emptive), 3 (Prophylaxis)  
Heterogeneity: Tau2=0.73; Chi2=1.45, df=1(P=0.23); I2=30.88%  
Test for overall effect: Z=0.01(P=0.99)  
   
2.7.2 CMV infection  
Khoury 2006 Kidney 7/13 7/16 44.37% 1.23[0.58,2.6]
Reischig 2008 Kidney 5/6 3/4 55.63% 1.11[0.57,2.17]
Subtotal (95% CI) 19 20 100% 1.16[0.71,1.92]
Total events: 12 (Pre-emptive), 10 (Prophylaxis)  
Heterogeneity: Tau2=0; Chi2=0.05, df=1(P=0.83); I2=0%  
Test for overall effect: Z=0.59(P=0.55)  
Test for subgroup differences: Chi2=0.02, df=1 (P=0.89), I2=0%  
Preemptive 1000.01 100.1 1 Prophylaxis
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Analysis 2.8.   Comparison 2 Pre-emptive medication versus prophylaxis, Outcome 8 D+ or D-/R+ serostatus.
Study or subgroup Pre-emptive Prophylaxis Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.8.1 Symptomatic CMV  
Khoury 2006 Kidney 0/36 1/33 45.97% 0.31[0.01,7.27]
Reischig 2008 Kidney 0/30 3/30 54.03% 0.14[0.01,2.65]
Subtotal (95% CI) 66 63 100% 0.2[0.02,1.74]
Total events: 0 (Pre-emptive), 4 (Prophylaxis)  
Heterogeneity: Tau2=0; Chi2=0.12, df=1(P=0.73); I2=0%  
Test for overall effect: Z=1.46(P=0.15)  
   
2.8.2 CMV infection  
Khoury 2006 Kidney 22/36 7/33 33.39% 2.88[1.42,5.84]
Reischig 2008 Kidney 28/30 16/30 66.61% 1.75[1.24,2.48]
Subtotal (95% CI) 66 63 100% 2.07[1.25,3.42]
Total events: 50 (Pre-emptive), 23 (Prophylaxis)  
Heterogeneity: Tau2=0.07; Chi2=1.84, df=1(P=0.18); I2=45.53%  
Test for overall effect: Z=2.83(P=0)  
Pre-emptive 2000.005 100.1 1 Prophylaxis
 
 
Comparison 3.   Oral versus IV ganciclovir
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 All symptomatic CMV disease 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
2 All-cause mortality 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
3 Other infections 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
 
 
Analysis 3.1.   Comparison 3 Oral versus IV ganciclovir, Outcome 1 All symptomatic CMV disease.
Study or subgroup Oral ganciclovir IV ganciclovir Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Singh 2000 Liver 0/11 1/11 0.33[0.02,7.39]
Oral ganciclovir 1000.01 100.1 1 IV ganciclovir
 
 
Analysis 3.2.   Comparison 3 Oral versus IV ganciclovir, Outcome 2 All-cause mortality.
Study or subgroup Oral ganciclovir IV ganciclovir Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Singh 2000 Liver 0/11 2/11 0.2[0.01,3.74]
Oral ganciclovir 2000.005 100.1 1 IV ganciclovir
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Analysis 3.3.   Comparison 3 Oral versus IV ganciclovir, Outcome 3 Other infections.
Study or subgroup Oral ganciclovir IV ganciclovir Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Singh 2000 Liver 5/11 5/11 1[0.4,2.5]
Oral ganciclovir 50.2 20.5 1 IV ganciclovir
 
 
A D D I T I O N A L   T A B L E S
 
  The Kidney Disease Improving
Global Outcomes (KDIGO 2009)
Caring for Australians with Renal Im-
pairment (CARI 2010)
British Transplant Society (BTS
2011)
Current rec-
ommenda-
tions to pre-
vent CMV
disease
Valganciclovir or IV ganciclovir
prophylaxis for at least 3 months
post renal transplantation and
for 6 weeks post T-cell depleting
immunosuppression.
No prophylaxis is required for re-
nal transplant patients who are
CMV seronegative and receive a
seronegative transplant
Valganciclovir, valaciclovir or IV ganci-
clovir for prophylaxis for 3 months. This
is extended to 6 months for high risk pa-
tients (D+/R-).
No prophylaxis is required for transplant
recipients who are CMV seronegative and
receive a seronegative transplant
Valganciclovir or IV ganciclovir for
prophylaxis 100 days post trans-
plantation.
No prophylaxis is required for re-
nal or liver transplant patients who
are seropositive for CMV and do
not receive T-cell depleting im-
munosuppression
Table 1.   Summary of CMV guidelines for solid organ transplant recipients 
 
 
A P P E N D I C E S
Appendix 1. Electronic search strategies
 
Database Search terms
CENTRAL 1. MeSH descriptor Cytomegalovirus, this term only in MeSH products
2. MeSH descriptor Cytomegalovirus Infections explode all trees in MeSH products
3. MeSH descriptor Cytomegalovirus Vaccines explode all trees
4. cytomegalovirus* in All Fields in CENTRAL
5. cmv* in All Fields in CENTRAL
6. (#1 OR #2 OR #3 OR #4 OR #5)
7. (organ or renal or kidney or heart or lung or liver or pancreas) adj transplant in All Fields in all
products
8. MeSH descriptor Organ Transplantation, this term only
9. MeSH descriptor Heart Transplantation explode all trees
10.MeSH descriptor Lung Transplantation explode all trees
11.MeSH descriptor Kidney Transplantation, this term only
12.MeSH descriptor Liver Transplantation, this term only
13.MeSH descriptor Pancreas Transplantation, this term only
14.(#7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13)
15.(#6 AND #14)
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Cochrane Database of Systematic Reviews
MEDLINE (OVID SP) 1. Cytomegalovirus/
2. exp Cytomegalovirus Infections/
3. Cytomegalovirus Vaccines/
4. cytomegalovirus.tw.
5. cmv.tw.
6. or/1-5
7. Organ Transplantation/
8. exp Heart Transplantation/
9. exp Lung Transplantation/
10.Kidney Transplantation/
11.Liver Transplantation/
12.Pancreas Transplantation
13.((organ or renal or kidney or heart or lung or liver or pancreas) adj transplant$).tw
14.or/6-12
15.and/6,15
EMBASE (OVID SP) 1. exp CYTOMEGALOVIRUS/
2. Cytomegalovirus Infection/
3. Cytomegalovirus Antibody/
4. Cytomegalovirus Vaccine/
5. cytomegalovirus.tw.
6. CMV.tw.
7. or/1-6
8. exp organ transplantation/
9. ((organ or renal or kidney or heart or lung or liver or pancreas) adj transplant$).tw.
10.or/8-9
11.7 and 10
  (Continued)
 
Appendix 2. Risk of bias assessment tool
 
Potential source of bias Assessment criteria
Low risk of bias: Random number table; computer random number generator; coin tossing; shuf-
fling cards or envelopes; throwing dice; drawing of lots; minimization (minimization may be imple-
mented without a random element, and this is considered to be equivalent to being random).
High risk of bias: Sequence generated by odd or even date of birth; date (or day) of admission; se-
quence generated by hospital or clinic record number; allocation by judgement of the clinician; by
preference of the participant; based on the results of a laboratory test or a series of tests; by avail-
ability of the intervention.
Random sequence genera-
tion
Selection bias (biased alloca-
tion to interventions) due to
inadequate generation of a
randomised sequence
Unclear: Insufficient information about the sequence generation process to permit judgement.
Low risk of bias: Randomisation method described that would not allow investigator/participant to
know or influence intervention group before eligible participant entered in the study (e.g. central
allocation, including telephone, web-based, and pharmacy-controlled, randomisation; sequential-
ly numbered drug containers of identical appearance; sequentially numbered, opaque, sealed en-
velopes).
Allocation concealment
Selection bias (biased alloca-
tion to interventions) due to
inadequate concealment of al-
locations prior to assignment
High risk of bias: Using an open random allocation schedule (e.g. a list of random numbers); as-
signment envelopes were used without appropriate safeguards (e.g. if envelopes were unsealed or
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non-opaque or not sequentially numbered); alternation or rotation; date of birth; case record num-
ber; any other explicitly unconcealed procedure.
Unclear: Randomisation stated but no information on method used is available.
Low risk of bias: No blinding or incomplete blinding, but the review authors judge that the outcome
is not likely to be influenced by lack of blinding; blinding of participants and key study personnel
ensured, and unlikely that the blinding could have been broken.
High risk of bias: No blinding or incomplete blinding, and the outcome is likely to be influenced by
lack of blinding; blinding of key study participants and personnel attempted, but likely that the
blinding could have been broken, and the outcome is likely to be influenced by lack of blinding.
Blinding of participants and
personnel
Performance bias due to
knowledge of the allocated
interventions by participants
and personnel during the
study
Unclear: Insufficient information to permit judgement
Low risk of bias: No blinding of outcome assessment, but the review authors judge that the out-
come measurement is not likely to be influenced by lack of blinding; blinding of outcome assess-
ment ensured, and unlikely that the blinding could have been broken.
High risk of bias: No blinding of outcome assessment, and the outcome measurement is likely to be
influenced by lack of blinding; blinding of outcome assessment, but likely that the blinding could
have been broken, and the outcome measurement is likely to be influenced by lack of blinding.
Blinding of outcome assess-
ment
Detection bias due to knowl-
edge of the allocated interven-
tions by outcome assessors.
Unclear: Insufficient information to permit judgement
Low risk of bias: No missing outcome data; reasons for missing outcome data unlikely to be relat-
ed to true outcome (for survival data, censoring unlikely to be introducing bias); missing outcome
data balanced in numbers across intervention groups, with similar reasons for missing data across
groups; for dichotomous outcome data, the proportion of missing outcomes compared with ob-
served event risk not enough to have a clinically relevant impact on the intervention effect esti-
mate; for continuous outcome data, plausible effect size (difference in means or standardized dif-
ference in means) among missing outcomes not enough to have a clinically relevant impact on ob-
served effect size; missing data have been imputed using appropriate methods.
High risk of bias: Reason for missing outcome data likely to be related to true outcome, with either
imbalance in numbers or reasons for missing data across intervention groups; for dichotomous
outcome data, the proportion of missing outcomes compared with observed event risk enough to
induce clinically relevant bias in intervention effect estimate; for continuous outcome data, plausi-
ble effect size (difference in means or standardized difference in means) among missing outcomes
enough to induce clinically relevant bias in observed effect size; ‘as-treated’ analysis done with
substantial departure of the intervention received from that assigned at randomisation; potentially
inappropriate application of simple imputation.
Incomplete outcome data
Attrition bias due to amount,
nature or handling of incom-
plete outcome data.
Unclear: Insufficient information to permit judgement
Low risk of bias: The study protocol is available and all of the study’s pre-specified (primary and
secondary) outcomes that are of interest in the review have been reported in the pre-specified way;
the study protocol is not available but it is clear that the published reports include all expected out-
comes, including those that were pre-specified (convincing text of this nature may be uncommon).
Selective reporting
Reporting bias due to selective
outcome reporting
High risk of bias: Not all of the study’s pre-specified primary outcomes have been reported; one or
more primary outcomes is reported using measurements, analysis methods or subsets of the data
(e.g. subscales) that were not pre-specified; one or more reported primary outcomes were not pre-
specified (unless clear justification for their reporting is provided, such as an unexpected adverse
effect); one or more outcomes of interest in the review are reported incompletely so that they can-
not be entered in a meta-analysis; the study report fails to include results for a key outcome that
would be expected to have been reported for such a study.
  (Continued)
Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
63
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Unclear: Insufficient information to permit judgement
Low risk of bias: The study appears to be free of other sources of bias.
High risk of bias: Had a potential source of bias related to the specific study design used; stopped
early due to some data-dependent process (including a formal-stopping rule); had extreme base-
line imbalance; has been claimed to have been fraudulent; had some other problem.
Other bias
Bias due to problems not cov-
ered elsewhere in the table
Unclear: Insufficient information to assess whether an important risk of bias exists; insufficient ra-
tionale or evidence that an identified problem will introduce bias.
  (Continued)
 
W H A T ' S   N E W
 
Date Event Description
16 January 2013 New search has been performed Five studies identified and included
16 January 2013 New citation required and conclusions
have changed
New outcome data available
 
H I S T O R Y
Protocol first published: Issue 1, 2005
Review first published: Issue 1, 2006
 
Date Event Description
19 January 2010 Amended Contact details updated.
13 August 2009 Amended Contact details updated.
14 October 2008 Amended Converted to new review format.
 
C O N T R I B U T I O N S   O F   A U T H O R S
2013 review update• DO, AW, GS, KK and EH contributed to the data extraction, quality assessment, data analysis and rewriting of the review update.
2005 review• EMH identified and extracted data from included studies, contacted authors, analysed and interpreted the results and wrote the
manuscript.• CAJ conceived, designed and developed the protocol and search strategy for the review, identified and extracted data from included
studies and participated in revision of the manuscript.• GFMS checked the analysis and interpretation of the results and participated in the revision of the manuscript.• KK identified and extracted data from included studies and participated in revision of the manuscript.• JCC conceived, designed and developed the protocol, analysed and interpreted the results and edited the dra@ing and revision of the
manuscript.
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D E C L A R A T I O N S   O F   I N T E R E S T
None known.
S O U R C E S   O F   S U P P O R T
Internal sources• Australia-Europe Endeavour Scholarship, 2005, Australia.• University of Sydney Program Grant PhD Scholarship, Australia.
External sources• No sources of support supplied
I N D E X   T E R M S
Medical Subject Headings (MeSH)
*Organ Transplantation;  Acyclovir  [therapeutic use];  Antiviral Agents  [*therapeutic use];  Cytomegalovirus Infections  [*prevention &
control];  Ganciclovir  [therapeutic use];  Immunocompromised Host;  Opportunistic Infections  [prevention & control];  Randomized
Controlled Trials as Topic;  Viremia  [*prevention & control]  [virology]
MeSH check words
Humans
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